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The human immunodeficiency virus type 1 (HIV-1) is the causative 
agent of acquired immunodefiency syndrome (AIDS), a disease that had 
affected at least 34 million people worldwide by the end of 2011. Anti-HIV 
drugs that are currently in use mainly target the active sites of viral enzymes 
such as reverse transcriptase or viral proteases. However, the high mutation 
rates of these active sites often lead to the rapid emergence of viral strains 
resistant to available drug regimes. As such, a new generation of antiviral 
drugs is necessary. HIV-1 establishes a permanent infection in the host cell 
when the viral DNA genome is integrated into host chromosomal DNA. This 
integration process is mediated by a cytoplasmic nucleoprotein complex, 
namely the preintegration complex (PIC), which comprises of core 
components including viral cDNA, integrase (IN) protein and other viral and 
cellular proteins. Despite the lack of knowledge on the exact structure and 
composition of the PIC, studies have demonstrated the exploitation of various 
cellular factors to modulate PIC activity thereby affecting HIV replication. 
Hence, understanding the molecular aspects of virus-host interactions in the 
integration step should provide new insights into alternative strategies for the 
treatment of HIV infection by targeting cellular factors. Since the new drug 
target is a host factor, it is also less likely that resistant viral strains will arise.  
Studies have shown that the HIV-1 integration is actively modulated 
via the ubiquitin-proteasome pathway, whereas the E3 ubiquitin ligase that 
regulates the PIC function has not been identified. The revelation of such will 
provide additional knowledge to the regulation of HIV-1 IN, potentially 
guiding the development of antiviral strategies targeting at the integration step. 
In our research, we developed an in vitro assay monitoring PIC integration in a 
high-throughput setting, to identify novel E3 ubiquitin ligases involved in HIV 
integration. The assay system is applied to a preliminary screen using an 
available human E3 ubiquitin ligase library of proteins. Amongst the candidate 
proteins identified, we found that RFPL3 enhances integration activity of 
HIV-1 PIC in vitro, and this effect was likely to be attributed to its N-terminal 
RING domain. Further study is required to fully elucidate its mechanism in the 
enhancement of HIV-1 integration. 
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CHAPTER 1: INTRODUCTION 
1.1 Introduction to HIV and its replication cycle 
The HIV is a lentivirus belonging to the Retroviridae family with two 
distinct species, namely HIV-1 and HIV-2. HIV-1 is more virulent and 
infectious, accounting for majority of HIV cases (Levy, 2009). The enveloped 
HIV-1 particle carries two copies of positive sense single-stranded RNA. Each 
strand is 9.7 kb in length and encodes three major proteins, namely the Gag, 
Pol and Env, as well as other regulatory and accessory proteins. Flanking the 
ends of the RNA are the 5' and 3' long terminal repeat (LTR) sequences that 
play important roles in the replication cycle.  
HIV-1 infects a spectrum of immune cells including CD4+ helper T 
cells, macrophages, and microglial cells (Cunningham et al., 2010). Its 
replication cycle can be classified into two phases—early and late phase 
(Figure 1.1). During the early phase, viral envelope (Env) glycoproteins 
recognize and interact with cell surface protein CD4, stimulating a 
conformational change that allows gp120 portion of Env to bind to other 
coreceptors such as chemokine receptor CXCR4 or CCR5. This induces the 
refolding of Env gp41 which then mediates membrane fusion and viral entry 
(Nisole and Saib, 2004). In the host cytoplasm, the virion begins to uncoat its 
capsid (CA) proteins to release the viral genome and other essential proteins, 
allowing reverse transcription to begin. Host cellular cofactors and essential 
viral enzymes such as reverse transcriptase (RT) and integrase (IN) form a 
reverse transcription complex (RTC) where they work in concert to produce 
viral DNA from the RNA genome (Warrilow et al., 2009). The newly 
synthesized viral DNA remains associated with various viral and host proteins, 
forming the preintegration complex (PIC). This PIC plays a major role in 
facilitating the integration of viral DNA into the host genome in the nucleus 
(Bushman and Craigie, 1991). Nuclear translocation of the PIC is conjectured 
to be mediated by the presence of karyophillic signals carried by either viral or 
cellular proteins that are part of the PIC, although the exact mechanism is 
poorly defined (Fouchier and Malim, 1999). 
 During the integration process, the HIV-1 establishes a permanent 
infection in the host cell when the viral DNA genome is inserted into host 
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chromosomal DNA. The integration process begins in the cytoplasm where IN 
catalyzes the 3’-end processing of the viral DNA. Following nuclear entry of 
the PIC, IN binds to and cleaves host chromosomal DNA to mediate strand-
transfer of the viral DNA. Finally, cellular repair enzymes fill up the nicked 
gaps to complete the integration process (Suzuki et al., 2011). The integrated 
viral DNA, now a provirus, is transcribed as part of the host genome, 
producing viral genes at the expense of host resources. 
 The late phase of the viral replication cycle begins with the 
transcription and translation of the viral RNA genome, consisting of the Gag, 
Pol and Env genes (Gallo et al., 1988). Precursor polyproteins including Gag 
(p65) and Gag-Pol (p160) were produced, of which the latter resulted from a 
ribosome frameshifting near the 3' end of Gag gene prior to the start of Pol 
(Jacks et al., 1988). The precursor polyproteins are subsequently cleaved by 
viral protease (PR) to form the matured forms of the structural and enzymatic 
proteins including IN. Eventually, packaged virions bud out of the host cell 
membrane and the matured progenies can then begin the next round of 
infection (Al-Mawsawi and Neamati, 2007). 
 
 
Figure 1.1: An overview of the HIV-1 replication cycle. Early phase of the cycle include 
viral entry, reverse transcription of viral RNA, nuclear translocation and integration of viral 
cDNA. Late phase of the cycle involves proviral gene expression and viral RNA translation 
using host machineries, assembly of new virion progenies, budding, maturation and infection 
of new targets. (Al-Mawsawi and Neamati, 2007) 
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1.2 HIV-1 mortality and challenges in the current treatment 
HIV remains a mortality threat with 34 million people infected 
worldwide at the end of 2011 (UNAIDS, 2012). Although there is no cure for 
HIV, there are at present 34 antiretroviral drugs (ARVs) approved by US Food 
and Drug Administration (FDA) for the control of HIV infection. A majority 
of these ARVs are inhibitors that target viral enzymes essential to various 
stages of the viral replication cycle, including RT, PR and IN. A compelling 
regimen for HIV infection involves a cocktail of ARVs, and this forms the 
basis of a typical highly active antiretroviral treatment (HAART) (Arts and 
Hazuda, 2012).  However, these inhibitors act on the active sites of their target 
viral proteins. Since the HIV has a relatively short replication cycle and its 
reverse transcriptase replicates with low fidelity, these viral enzyme active 
sites have an innately high rate of mutation (FDA, 2013). As a result, the 
mutations often lead to the emergence of drug resistant viral strains that are 
able to evade and survive the actions of their respective ARV inhibitors. 
Consequently, existing ARVs are usually unable to suppress plasma viremia in 
long term. Clinical trials on two strand-transfer inhibitors which target the 
HIV integration process, raltegravir and elvitegravir, revealed that resistant 
mutants, which developed from the therapy eventually, became cross-resistant 
to both first and second generation strand transfer inhibitors, challenging the 
effectiveness of subsequent treatments with drugs of the same class (Busschots 
et al., 2009).  
In addition, the complex combination of various ARVs often brings 
about an avalanche of undesirable drug toxicities and drug-drug interactions 
(DeJesus, 2007). In light of these shortcomings, there is a need for new 
therapeutic methods for the effective management of chronic HIV infection. 
These methods must not only aim to suppress plasma viremia, but also to 





1.3 Developing novel therapeutics through targeting host-pathogenic 
crosstalk  
Protein-protein interaction (PPI) is a common feature found nearly in 
all biological functions and is important for cells to mediate activities and 
responses. In HIV-1, multiple PPIs between viral proteins and host cellular 
cofactors have been identified, many of which mediate crucial steps in the 
replication process (Busschots et al., 2009). Although PPIs could also serve as 
attractive targets of drugs for HIV treatment, targeted inhibition of such PPIs 
were previously thought to be challenging, having to disrupt multitude of 
weak interactions across a wide protein interface (Domling, 2008). However, 
it was later discovered that the binding of a protein to another actually 
involves a narrow and highly structured interaction ‘hotspot’ where binding 
free energy greatly concentrates (Bogan and Thorn, 1998), exhibiting a 
potential site for specific targeted inhibition of the PPI. For the past decade, 
much attention from drug discovery studies has been given to the development 
of small molecular PPI inhibitors (SMPPIIs) that bind to these hotspot regions 
as potentially druggable targets. Moreover, small target molecules can be 
produced economically and are usually permeable to the cell membrane, 
making them ideal for the design of oral drugs (Busschots et al., 2009). 
 SMPPIIs are promising compounds for the development of new 
generation drugs that target many resistance-prone diseases including cancers 
and viral infections. One main reason is that SMPPIIs are not directed at 
highly evolvable active site regions on viral enzymes, but at interaction sites 
between viral proteins and the cellular cofactors (Arkin and Wells, 2004). To 
date, several novel ARVs have been designed based on a similar principle as 
SMPPII, by inhibiting ligand-receptor interactions. Some have been placed 
under investigation and clinical trials, including Maraviroc (Selzentry), a small 
molecule entry inhibitor approved in 2007 for the treatment of HIV. The 
molecule acts by blocking the co-receptor of HIV infection, CCR5, to prevent 
its interaction with gp120 of Env (Patrick Dorr, 2005). Such applications 
clearly demonstrated the potential of SMPPIIs as a new generation of HIV 
drugs. However, to further develop novel ARVs that disrupt key processes in 
the HIV replication cycle, there is a need to understand and identify critical 
interaction and crosstalk involving viral proteins and host cellular cofactors.  
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1.4 HIV-1 integration—a key step in the HIV-1 replication cycle involving  
viral IN and a multitude of host factors 
HIV-1 relies heavily on the interplay between various host cellular 
cofactors and viral proteins throughout its replication cycle (Goff, 2007). After 
entry into the host cell, the HIV-1 genome will be reverse transcribed to 
produce double-stranded (ds) DNA. The viral DNA then associates with 
multiple important viral proteins, especially the IN, and other host proteins to 
form the PIC in the cytoplasm. Critical crosstalk between specific host factors 
and viral proteins within the PIC is important to facilitate the nuclear 
translocation of the viral genome for subsequent integration into the host 
chromosome. Within the nucleus, HIV-1 integration occurs with the help of a 
critical viral enzyme, the IN protein, and other essential host factors, marking 
a key step in the viral replication cycle. Once integrated, the provirus cannot 
be differentiated nor excised out of the original host chromosomal DNA, 
establishing a permanent infection in the host cell. The provirus serves as a 
template for the efficient transcription of viral RNA and translation of viral 
proteins to be packaged into new viral progenies for infection of new-targeted 
host cells upon release. Therefore, integration of the viral genome is often 
deemed as the critical rate-determining step within the HIV-1 replication 
cycle, which significantly contributes to the infectivity of the retrovirus, 
making the process an attractive target in the treatment of retroviral infectious 
diseases (Lewinski and Bushman, 2005). 
1.4.1 HIV-1 IN protein 
IN is an essential viral enzyme that catalyzes the insertion of viral 
DNA into the host genome during integration. It is expressed at the C-terminal 
part of the Gag-Pol precursor polyprotein along with other essential viral 
proteins such as RT and PR. Upon budding and maturation, the viral PR 
cleaves the precursor protein to generate a mature form of IN (Swanstrom and 
Wills, 1997). HIV-1 IN is 32 kDa in size and contains three domains, namely 
the N-terminal domain (NTD), the catalytic core domain (CCD) and the C-
terminal domain (CTD) (Figure 1.2). The NTD consists of a HHCC motif, 
with two histidines and two cysteines, making up a zinc-binding site that is 
relatively well conserved amongst the IN of all retroviruses and 
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retrotransposons (Craigie, 2001). The domain is important for the 
multimerization and catalytic function of HIV-1 IN during integration. The 
CCD is also a highly conserved region that recognizes viral DNA and exhibits 
DNA binding ability, allowing retroviral IN to mediate strand transfer reaction 
during integration. In contrast, CTD is the least conserved domain that 
exhibits strong non-specific DNA-binding activity in vitro. Its catalytic 
function however is the most poorly understood of the three, though some 
studies suggested that the domain is important for integration specificity and 




Figure 1.2: Structural domain of HIV-1 IN. IN contains 288 amino acid residues and has 
three protein domains. The NTD facilitates protein dimerization, CCD is involved in the 
catalysis of integration, and CTD has DNA-binding activity (Suzuki et al., 2011). 
 
1.4.2 The mechanism of HIV-1 integration process 
 The HIV-1 integration process consists of three biochemical reactions 
(Figure 1.3). IN initially recognizes and interacts with the viral attachment 
(att) sites on both ends of the LTRs to carry out the 3’ processing of viral 
DNA. In this process, IN catalyzes the removal of two nucleotide base pairs 
adjacent to the highly conserved CA dinucleotide from the 3’ LTR region, in 
the presence of water as a nucleophile. The subsequent formation of 3’ 
hydroxyl radicals at the terminal ends chemically activates the viral DNA for 
the next reaction. In the second strand transfer step, IN brings the activated 
viral DNA in close proximity with the target DNA. Upon nucleophilic attack 
by the 3’ hydroxyl radical, the target DNA is cleaved to allow the insertion of 
the viral DNA. IN then ligates the 3’ hydroxyl radical terminal of the viral 
DNA to the 5’ phosphoryl ends of the target host DNA, forming intermediate 
DNA products with unrepaired gaps. Lastly, after ligation, the unrepaired gaps 
are filled up to produce fully functional integrated proviruses. As a result, 
these repaired gaps led to the formation of imperfect inverted repeats in the 
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form of short duplication of the target DNA flanking both ends of the inserted 
viral genome (Craigie, 2001). The final repair step is likely to be mediated by 
host repair enzymes from various repair pathways, including that of 
nonhomologous end joining (NHEJ), though the exact machinery and specific 
enzymes involved are yet to be confirmed (Smith and Daniel, 2006).   
 
 
Figure 1.3: Illustration of the 3 biochemical steps in HIV-1 integration. The first step 
involves a 3’ processing of the viral genome catalyzed by IN. This is followed by strand-
transfer whereby IN mediates the insertion of the 3’-OH ends of the viral DNA into the 5’ 
phosphoryl ends of the target DNA. Finally, IN is released, making space for repair enzymes 








1.4.3 Host proteins found to associate with HIV-1 IN 
Although HIV-1 IN plays a principle role in catalyzing the integration 
reaction, it is also a pleiotropic protein participating in other various stages of 
the virus replication cycle, including reverse transcription, RTC and PIC 
formation, nuclear translocation and virion assembly (Al-Mawsawi and 
Neamati, 2007). Interestingly, multiple host cellular cofactors have been 
discovered to interact with IN at different stages of the replication cycle, 
through co-immunoprecipitation, affinity pull-down and yeast two-hybrid 
assays (Turlure et al., 2004). These host interactions therefore would be a 
primary basis for the function and pleiotropic effects of HIV-1 IN (Table 1).  
Gemin2, also known as the survival motor neuron (SMN) interacting 
protein 1, is a component of the SMN complex which mediates the biogenesis 
of spliceosomal small nuclear ribonucleoproteins (snRNPs) and the assembly 
of nucleolar ribonucleoproteins (snoRNP) (Fischer et al., 1997). The protein 
was first found to interact with HIV-1 IN through yeast two-hybrid screening. 
It was further demonstrated that Gemin2 depletion using small interfering 
RNA (siRNA) significantly reduced HIV-1 infection in human primary 
monocyte-derived macrophages, accompanied by a reduction in viral cDNA 
synthesis. Conversely, the siRNA did not affect HIV-1 expression from the 
integrated DNA. Hence, IN-Gemin2 interaction was postulated to play an 
essential role in facilitating efficient reverse transcription during the 
production of viral cDNA after entry, a step that precedes viral DNA 
integration (Hamamoto et al., 2006).  
After reverse transcription, the newly synthesized viral DNA remains 
associated with viral proteins such as IN and other cellular factors to form the 
PIC. The PIC has been stipulated to contain karyophilic properties, allowing 
the latter to be shuttled into the nucleus and for the integration of viral DNA 
into host chromosome (Suzuki and Craigie, 2007). The exact components 
contributing to the active nuclear import of PIC remains unknown, but a few 
nuclear transporters have been found to interact with IN, supposedly playing 
an important role in directing PICs into the nucleus. These include two 
importins, importin 7 and TNPO3 as well as a nucleoporin, NUP153 (Ao et 
al., 2007; Christ et al., 2008; Woodward et al., 2009). Importin 7 and TNPO3 
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both belong to the importin  family, which specifically recognises and 
transport its cargo molecules into the nucleus through association with 
nucleoporins of the nuclear pore complex (Suzuki and Craigie, 2007). 
Importin 7 was initially found to associate with HIV-1 IN through affinity 
pull-down. Confocal microscopy analysis of permeabilized infected human 
cells also revealed accumulation of the IN and importin 7 within the nucleus. 
In experiments involving IN-importin7 interaction-deficient mutant, viral 
reverse transcription and nuclear import steps were both clearly impaired, 
indicating the importance of importin 7 for viral replication particularly in the 
early phase. (Ao et al., 2007; Fassati et al., 2003; Zaitseva et al., 2009). 
TNPO3 was identified to be an interacting host partner of IN through yeast 
two-hybrid screening. Experiments involving the knockdown of TNPO3 in 
primary macrophages also led to reduced 2-LTR formation in the nucleus, an 
indication of impaired nuclear import of the viral genome.  Hence, TNPO3 is 
stipulated to be involved in the nuclear import of PIC, required for efficient 
HIV-1 replication (Christ et al., 2008). Lastly, NUP153 was also pulled down 
together with HIV-1 IN through an in vitro experiment, revealing its 
association and possible involvement in the nuclear import of HIV-1 
complexes, though recently it has been pointed out that the viral determinant 
could be the CA proteins more than the interaction with IN per se (Matreyek 
and Engelman, 2011; Woodward et al., 2009).  
Once in the nucleus, many other host factors continue to interact with 
IN to ensure an efficient and complete integration of the viral genome into the 
host chromosome. The lens epithelium-derived growth factor (LEDGF), 
alternatively known as transcriptional coactivator p75 (LEDGF/p75), is a 
transcriptional regulator of stress response related genes that binds to the 
promoter regions of heat-shock and stress-related elements (Singh et al., 
2001). LEDGF belongs to the hepatoma-derived growth factor family, and 
was one of the first cofactors found to interact with HIV-1 IN through a co-
immunoprecipitation analysis using FLAG-tagged IN (Cherepanov et al., 
2003). During HIV-1 replication, LEDGF initially associates with PIC in the 
cytoplasm, protecting IN from ubiquitination and degradation (Llano et al., 
2004). The LEDGF gene also contains sequences that encode for nuclear 
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transport signal (Maertens et al., 2003) allowing the protein to be involved in 
the nuclear translocation of IN and the viral genome, along with other import 
proteins present within the PIC. However, the main role of LEDGF is in fact 
to stimulate integration activity once in the nucleus. LEDGF is an adaptor 
protein that acts as a tethering factor, bringing IN within close proximity of 
nuclear chromatin (Figure 1.4B) thereby increasing the affinity of IN to DNA 
by more than 33-fold, for IN to efficiently catalyze the insertion step 
(Busschots et al., 2005). Infection studies in human CD4+ T cells and mouse 
embryo fibroblasts had revealed a significant reduction of HIV-1 infection 
upon elimination of endogenous LEDGF (Shun et al., 2007), indicating an 
essential role of the protein in mediating viral replication and infectivity. 
Other than the adaptor protein LEDGF mentioned above, RAD51 is 
another homologous recombination (HR) protein that can modulate the 
efficiency of integration by interacting with IN. Human RAD51 belongs to the 
RAD52 epitasis group involved in mitotic HR events as well as chromosome 
segregation during meiosis. When energy molecule ATP is present, RAD51 
polymerizes on DNA to form a nucleoprotein filament that serves as a 
catalytic center for DNA strand transfer reactions during HR events (San 
Filippo et al., 2008). The formation of the nucleoprotein filament was found to 
strongly inhibit the efficiency of HIV-1 IN through the displacement of the 
latter, causing the process of HIV-1 integration to be greatly restricted 
(Cosnefroy et al., 2012). Yet, in another study using primary human microglial 
cells, RAD51 was shown to exhibit an enhancing effect on the transcriptional 
activity of HIV-1 in the early replication cycle, by promoting the binding of 
transcription factor NFB to the LTR region for transcriptional activation 
(Rom et al., 2010). Hence, RAD51 may hold a controversial effect on HIV-1 
replication depending on the stage at which the host factor gets associated with 
the replication complexes, whether in the cytoplasm or the nucleus, which 
remains a doubt yet to be determined. 
Histone acetyl transferases (HATs) are enzymes that acetylate the ε-
amino group of basic lysine residues of histone’s N-terminal, modifying the 
accessibility of DNA by other proteins (Roth et al., 2001). p300 was the first 
HAT protein found to acetylate HIV-1 IN, leading to greater binding affinity 
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of the latter to LTR DNA and enhanced strand transfer activity. It is a nuclear 
phosphoprotein of approximately 300 kDa and initially isolated as an 
interaction partner of adenovirus E1A (Sterner and Berger, 2000).  An in vitro 
study using recombinant p300 and HIV-1 IN revealed 3 specific lysine 
residues on the C-terminal region of HIV-1 IN where p300 directly binds to 
and acetylates, including Lys-264, Lys-266 and Lys-273. In virus-infected 
CD4+ T cells and primary peripheral blood lymphocytes expressing mutant IN 
containing arginine substitutions on these critical lysine residues, HIV-1 
replication was observed to be greatly impaired, and the defect was largely 
occurring at the integration step of the replication cycle, supporting the 
requirement of proper IN acetylation by p300 in mediating efficient HIV-1 
integration (Cereseto et al., 2005). 
In contrast to HATs, another host factor, KAP1, was found to interact 
with acetylated IN through a unique yeast two-hybrid screening assay 
(Allouch et al., 2011). KAP1, also known as TRIM28, is a transcriptional 
corepressor belonging to the TRIM family of proteins that contains the 
characteristic RBCC domain at the N-terminal consisting of a ring finger, two 
B-box zinc fingers and a coiled coil. The protein has been reported to form 
complexes with histone deacetylases (HDAC) causing the modification of 
histone structures and hence down-regulation of gene transcription (Iyengar 
and Farnham, 2011). Experiments performed with the knockdown or 
overexpression of KAP1 protein revealed that the latter specifically inhibits 
the integration reaction in HIV-1-infected cells. The level of acetylated IN was 
also shown to be decreased with higher expression of KAP1 in cells. 
Furthermore, in co-immunoprecipitation experiments, it was observed that 
HIV-1 IN associates with KAP1 and a histone deacetylase protein, HDAC1 
(Allouch et al., 2011). Hence, it was proposed that KAP1 could play the role 
of a scaffolding mediator that recruits HDAC to acetylated IN, causing the 
deacetylation of the latter and subsequent reduction in HIV-1 integration 
efficiency as a whole.  
A summary on the effects and method of identification of the 
abovementioned host factors that interact with IN in the early phase of the 
HIV-1 replication cycle can be found in Table 1.1 below. Research on the 
identified host factors is still ongoing to validate these interactions and their 
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importance in the HIV-1 replication cycle for the development of new 
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Table 1.1: List of cellular cofactors that interact with IN to modulate HIV-1 replication 











 1.5 Ubiquitination and phosphorylation of HIV-1 IN by host factors 
Despite the identification of several host interactors of HIV-1 IN, 
research effort in the search of more host factors is still strong, especially for 
those believed to play a much significant role in HIV-1 replication. One such 
example would be the identification of a host factor likely to be implicated in 
the regulation of the stability and degradation of IN in a manner that restricts 
the critical integration process.   
1.5.1 Role of protein kinases in stabilization of HIV-1 IN 
Protein kinase has been shown to be involved in the regulation of IN 
stability through phosphorylation of the viral protein. The c-Jun NH2-terminal 
kinase (JNK), which was found to phosphorylate HIV-1 IN, consequently 
contributes to an efficient infection and integration of HIV-1 (Manganaro et 
al., 2010). JNK belongs to one of the major groups of mitogen-activated 
protein kinases (MAPKs), a family of serine/threonine kinases involved in 
signal transduction from extracellular stimuli including growth factors, 
cytokines, infection and stress. HIV-1 IN was observed to be phosphorylated 
on a serine residue Ser-57 found in its CCD region through an 
immunoprecipitation assay using lysates from HIV-1 infected and activated 
cells expressing substantial levels of JNK. Conversely, in lysates of infected 
cells treated with a specific JNK inhibitor SP600125, phosphorylated IN could 
not be detected, supporting the observation that JNK is responsible for the 
phosphorylation of IN during HIV-1 infection. Furthermore, HIV-1 infection 
was impaired and decreased amounts of integrated DNA was observed in 
HIV-1 infected cells treated with JNK inhibitor, indicating that JNK-mediated 
phosphorylation of IN is important for the efficient infection and integration of 
HIV-1 (Manganaro et al., 2010). It was additionally reported that the 
stabilization of IN from JNK phosphorylation also involves another host 
factor, the peptidyl-prolyl cis-trans isomerase, namely Pin1. Pin1 specifically 
recognizes the phosphorylated Ser-57 and catalyzes a structural rearrangement 
of a target molecule through cis-trans isomerisation of the preceding proline 
residue, Pro-58 (Lu and Zhou, 2007). Such structural rearrangement by Pin1 
has also been observed in multiple other substrate proteins including NF-B 
p65 and β-catenin, causing the stabilization of the latter and contributing to 
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profound functional effects on their activities (Ryo et al., 2001; Ryo et al., 
2003). Indeed, in the case of HIV-1 IN, when recombinant IN was incubated 
with Pin1, there was increased resistance of IN against protease, indicating 
reduced sensitivity to protein degradation. When infected cells were treated 
with Pin1 inhibitor, Pib, decreased IN stability was observed and integration 
activity was severely impaired (Manganaro et al., 2010). Hence, the JNK-
mediated phosphorylation leading to Pin1 recognition and subsequent 
structural stabilization of IN demonstrated the concerted effect of host proteins 
contributing to the enhanced integration efficiency in HIV-1 infected cells. 
Perhaps this is also a good example to guide research work for antiviral 
strategies towards studying a complex of host factor interactions rather than 
the isolated host factor with recombinant IN per se.  
1.5.2 Involvement of ubiquitin ligases in the degradation of HIV-1 IN 
On the other hand, it is also interesting to look into host factors 
involved in the degradation of HIV-1 IN, so as to derive antiviral strategies 
that can specifically and effectively impair the integration process to restrict 
viral infection. It has been demonstrated that IN is being actively degraded 
through the ubiquitin-proteasome pathway (Devroe et al., 2003; Mulder and 
Muesing, 2000). In the ubiquitin conjugation pathway, an E1 enzyme first 
activates by adding ubiquitin to another E2 ubiquitin-conjugating enzyme, 
which in turn transfers the ubiquitin to a lysine residue on the substrate protein 
to be marked for proteasomal sequestration. This transfer usually involves an 
E3 ubiquitin-protein ligase that provides substrate specificity. There are two 
main classes of E3 ligases, the homologous to E6-APC terminus (HECT)-type 
E3, which displays direct catalytic effect, as well as the single or multisubunit 
RING-H2–type E3s that promote ubiquitination by bringing the active E2 in 
close proximity with the substrate molecule (Metzger et al., 2012).  
A recent study has reported the degradation of HIV-1 IN by the culin2  
(Cul2)-based von Hippel-Lindau (VHL) ubiquitin ligase through the ubiquitin-
proteasome pathway. Additionally, it was observed that a von Hippel-Lindau 
binding protein 1 (VBP1), a subunit of the prefolding chaperone is required as 
an IN cellular binding partner to bridge the interaction between IN and the 
VHL for its subsequent proteasome-mediated degradation. However, VBP1 
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and VHL knockdown in HIV-1 infected cells specifically inhibited viral 
transcription without significantly affecting the amount of reverse transcribed 
viral DNA and the integrated DNA product, suggesting a role for the proteins 
in the post-integration event rather than the early phases. Also, VBP1 was not 
required for HIV-1 transcription when the integration step was bypassed with 
the direct transfection of the viral genome, further supporting the fact that 
VBP1 and VHL are required to degrade IN from the viral DNA after 
integration for a proper transition and efficient transcription of the integrated 
viral genome. The authors therefore suggested the role of post-integration 
degradation of IN to be necessary for the correct repair of integration 
intermediate, enabling an efficient viral transcription to occur (Mousnier et al., 
2007).  
 Another study also identified a HECT-type E3 ubiquitin ligase, Huwe1 
to be a novel cellular interactor of HIV-1 IN. The protein was initially 
identified to be the E3 ligase involved in the ubiquitination of tumour 
suppressors p53 and c-Myc (Chen et al., 2005a; Zhong et al., 2005). Although 
Huwe1 was found to interact with HIV-1 IN through a tandem affinity 
purification (TAP) procedure, this cofactor was also associated with IN region 
of Gag-Pol precursor protein. It was observed that knockdown of endogenous 
Huwe1 could lead to increasing infectivity of HIV-1 virions released in CD4+ 
T cells, suggesting that Huwe1 possibly yields a negative impact on the 
formation of infectious HIV-1 particles, rather than restricting HIV-1 
replication through the degradation of the active IN protein. A possible 
explanation is that Huwe1 could interact and sequester a Gag-Pol precursor 
through the IN region and subsequently interfere with the localization of Gag-
Pol to the plasma membrane where assembly of virus particles occurs 
(Yamamoto et al., 2011). 
 Although studies have identified ubiquitin ligases involved in the 
regulation of HIV-1 replication, VBP1 was found to degrade IN in a post-
integration step, which instead helps to promote HIV-1 infectivity by ensuring 
efficient viral gene transcription, whereas Huwe1 was found to restrict HIV-1 
infectivity by inhibiting proper virion production through sequestering the 
Gag-Pol precursor at the late step of virus replication. To date, the actual 
ubiquitin ligase that can regulate integration activity in the early phase has yet 
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to be identified. Hence, further work is required to identify novel ubiquitin 
ligases as such involved in the proteolytic pathways that affect the stability of 
HIV-1 IN before it catalyzes a permanent infection through integration.  
A summary of the kinases and ubiquitn ligases that interact with HIV-1 

















stabilizes IN for 
efficient integration  
(Manganaro 











et al., 2007) 


























 1.6 HIV-1 PIC as a better target of study than recombinant IN  
The crosstalk between host cellular proteins and IN present an 
interesting target for the development of SMPPII to restrict HIV-1 replication. 
However, although the act of integration is mainly executed by IN, a number 
of studies have shown that a complete in vivo integration requires the 
cytoplasmic nucleoprotein complex, the PIC (Farnet and Bushman, 1997; 
Fujiwara and Mizuuchi, 1988). While purified recombinant IN does display in 
vitro integration activity, majority of the products were often incomplete and 
only one end of the viral DNA was joined to target DNA. In contrast, when 
PICs isolated from infected cells were used in place of purified IN, integration 
efficiency was greatly improved, allowing the yield of complete two-ended 
products even under in vitro conditions (Bushman and Craigie, 1991; Farnet et 
al., 1996). Integration activity for recombinant IN and PIC has also been 
compared using integration inhibitors, and the results revealed that many 
inhibitors active against the purified IN protein in vitro were eventually futile 
against PICs (Farnet et al., 1996). Indeed, the integration reaction involves a 
complex web of interaction amongst IN and many other host factors, at times 
requiring more than one host factor to exert a full interaction effect on the 
activity of IN, as seen from known examples such as KAP1/HDAC1 and 
JNK/Pin1 (Allouch et al., 2011; Manganaro et al., 2010). Hence, analyzing the 
nucleoprotein complex PIC should be better in revealing further details of the 
complicated nucleocomplex structure and other interactions with host factors 
that may be important to the function and reproduction of authentic retroviral 
integration. In light of this, in vitro monitoring and high-throughput screening 
performed using PIC should also be more promising in allowing the modelling 
of in vitro conditions closer to that of the physiological conditions, thereby 
providing a more reliable identification of possible candidates that 






1.6.1 Cellular components and modulators of the pre-integration 
nucleoprotein complex (PIC) 
The PIC, a key nucleoprotein complex responsible for integration, is 
composed of not only viral proteins but also several other cellular proteins 
(Goff, 2001). Viral components of the HIV-1 PIC include IN, RT, matrix, CA 
and other accessory proteins (Suzuki and Craigie, 2007). However, the cellular 
components of the PIC are less well understood, though researchers have 
identified some of them through in vitro reconstitution analysis using 
recombinant proteins and immunoprecipitation assays of PICs using specific 
antibodies (Table 1.2). The identification of the PIC cellular components is 
therefore important for the understanding of how the PIC activity is modulated 
in infected cells.  
Barrier-to-autointegration factor (BAF) is a cellular protein that binds 
to DNA in a non-specific manner (Zheng et al., 2000). This protein was first 
identified as a cellular cofactor of Moloney murine leukemia virus (MoMLV-
1) PIC through a BAF reconstitution assay. MoMLV PICs were initially 
isolated from infected cells and subjected to high-salt treatment to remove 
cellular components that promote integration activity of the PIC. 
Subsequently, the salt-stripped PICs were reconstituted by adding various 
fractions derived from uninfected cells, and in vitro integration activity assay 
was then performed. When the resultant integrated products were checked 
using southern blotting analysis, the fractions containing BAF were found to 
restore integration activity of the salt-stripped PICs (Lee and Craigie, 1998). 
BAF was reported to bind double-stranded DNA specifically through its helix-
hairpin-helix (HhH) motif, and the dimerized structure appears to cross-bridge 
DNA, thereby preventing any suicidal intramolecular autointegration of viral 
genome within the PIC. Consequently, being a component of the PIC, BAF 
helps to facilitate an efficient execution by promoting a complete 
intermolecular integration of viral cDNA into the host genome through its 
DNA-bridging activity (Suzuki and Craigie,, 2002).  
A similar method of reconstitution analysis also led to the 
identification of a HMGA1 protein as a component of the PIC (Farnet and 
Bushman, 1997). PICs isolated from HIV-1 infected cells were subjected to 
high-salt treatment and the addition of an extract from uninfected cells 
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subsequently restored activity, and by fractionating the complementing 
activity, a nonhistone chromosomal protein, HMG I(Y), was identified as a 
functional component of the HIV-1 PIC. Notably, purified HMG I(Y) alone 
was insufficient to carry out integration when mixed with target viral cDNA, 
indicating its role as an accessory factor for the function of HIV-1 PICs. The 
exact mechanism by which HMG I(Y) is not conclusive as yet, but available 
data seemed to point at a proposed role of the protein towards binding and 
modifying the chromosomal architecture of viral cDNA within the PIC so as 
to facilitate an efficient strand transfer reaction (Farnet and Bushman, 1997).  
In addition to the reconstitution assay, co-immunoprecipitation 
analysis using antibodies against plausible candidates, such as known IN 
interactors, has been commonly used to identify the cellular components of the 
PIC. Ku70 is a well-known DNA repair protein involved in the 
nonhomologous end-joining (NHEJ) repair pathway (Downs and Jackson, 
2004). In a recent study, Ku70 was identified as a host protein that binds HIV-
1 IN at residues 230-288 of its C terminus domain through a yeast two-hybrid 
analysis (Studamire and Goff, 2008). It was shown that Ku70 binding to IN 
could specifically reduce the ubiquitination levels of IN, demonstrating a 
possible masking effect of the ubiquitin attachment sites in IN as a result of 
the interaction, consequently protecting the latter from degradation. Parallel to 
this observation, knockdown of Ku70 expression in CD4+ T cells also revealed 
disruption to HIV-1 replication with reduced integrated products, indicating 
the importance of Ku70 in stabilizing IN activity to mediate the early phases 
of HIV-1 replication including integration. Upon further immunoprecipitation 
analysis, the authors finally concluded Ku70 to be a component of HIV-1 PIC 
that binds and interacts with IN within the complex. The results suggested that 
Ku70 is likely to associate with the PIC in the early stage of the replication 
cycle to possibly protect IN from host proteasomal degradation. Following the 
nuclear import of the PIC, it then assists the IN further during the execution of 
integration within the nucleus (Zheng et al., 2011).  
Following the identification of BAF protein as a component of PIC, it 
has led to further conjectures that interactors of BAF could potentially be a 
component of the HIV-1 PIC. BAF has been shown to interact with members 
of the LEM protein family (Lee et al., 2001; Shumaker et al., 2001). LEM 
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proteins are polypeptides that make up the nuclear lamina structure of the 
nuclear periphery, required for the maintenance of nuclear shape and the 
spacing of nucleopore complexes, as well as in other functions such as DNA 
replication and the regulation of transcriptional factors (Foisner, 2001). 
Indeed, immunoprecipitation analysis of various LEM proteins eventually led 
to the identification of lamina-associated polypeptide 2α (LAP2α) and emerin 
as two other components of the HIV-1 and MoMLV PICs (Jacque and 
Stevenson, 2006; Suzuki et al., 2004). LAP2α was found to play the main role 
of stabilizing the association of BAF with MoMLV PIC to mediate efficient 
intermolecular integration by preventing autointegration of the viral genome 
(Suzuki et al., 2004). Emerin was also found to associate with BAF within the 
HIV-1 PIC, for the proposed function of facilitating chromatin engagement by 
viral cDNA before integration, though more work needs to be done to confirm 
the importance of emerin-BAF interactions on HIV-1 infectivity (Jacque and 
Stevenson, 2006). 
Other than the LEM proteins, BAF can also be regulated by 
phosphorylation via a family of cellular serine/threonine kinases namely the 
vaccinia-related kinases (VRK). Among the VRK family, VRK1 and VRK2 
were able to catalyze the N-terminal phosphorylation of BAF, consequently 
leading to the loss of DNA binding activity of BAF in vitro. In addition, there 
is also reduced interaction between phosphorylated BAF and the LEM domain 
in the nuclear matrix, leading to the redistribution of BAF throughout 
cytoplasmic pools in vivo (Nichols et al., 2006). In conclusion, VRKs were 
shown to be an important cytosolic factor that negatively modulate PIC 
activity during infection, by phosphorylating BAF and causing its dissociation 
from the retroviral integration complex, leading to impaired integration 
(Suzuki et al., 2010).  
The cellular components and modulators of retroviral PIC that have 
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Table 1.3: List of cellular components/modulators of PIC identified by various group of 










1.6.2 Hurdles to the use of PICs in high-throughput screening studies  
The discovery of VRKs as negative modulator of PIC demonstrated the 
need for the identification of PIC-associated cellular factors components for 
future development of new therapeutic strategy for HIV treatment. However, 
using the in vitro reconstitution method to identify novel constituent of the 
PIC has been a tedious procedure and often multiple experiments are required 
before novel cellular components or modulators of the PIC can be identified. 
On the other hand, immunoprecipitation analysis often requires prior 
knowledge of candidate interactors based on preliminary interaction studies of 
the protein in isolation for the inference of potential interaction factors. Hence, 
it is considerably arduous to resolve the cellular components of the PIC or 
even identify modulators of PIC activity based on reconstitution or pull-down 
assays (Turlure et al., 2004). 
Conventional assays to detect integration activity of retroviral PICs are 
also laborious, which involves time-consuming southern blotting analysis and 
the use of radioisotopes, lacking the simplicity required of high-throughput 
screening studies for identification of new cellular cofactors (Hansen et al., 
1999). As a result, only several components and modulators of PIC have been 
identified to date (Suzuki et al., 2012), and the exact components and other 
interacting partners of the PIC still remain unknown, hampering a complete 
understanding of the molecular aspects of retroviral integration. The lack of an 
efficient screening system in the nature of such experiments is likely to 
impede the development of novel antiviral agents that can target these cellular 
components or modulators of PIC in the treatment of HIV-1 infection. An 
alternative method of identification is therefore needed that can allow an 
efficient and accurate revelation of the unknown components and modulators 







 1.7 Aims and objectives   
In light of the abovementioned issues, the primary specific aim in our 
project is to directly identify new host cofactor proteins that modulate HIV-1 
PIC activity in vitro by adopting a newly developed PIC integration assay 
system in a high-throughput setting. By coupling with a sensitive quantitative 
PCR (qPCR) system to detect the amount of integrated products, we have 
developed a rapid in vitro PIC integration assay that can be performed in 96-
well microtiter plates for monitoring the integration activity of the HIV PIC 
without the use of autoradiography. In the first stage, we aimed to combine 
this rapid PIC assay with a high-throughput protein production system 
(Goshima et al., 2008) to identify cellular factors involved in PIC activity. We 
have chosen to focus on a RING-type human E3 ubiquitin ligase library of 
proteins since, as mentioned above, E3 ligases are likely involved in the 
degradation of HIV-1 IN and are thus potential modulators of PIC activity 
(Mulder and Muesing, 2000). The human E3 ubiquitin ligases were 
synthesized by the wheat germ cell-free protein expression system (Takai et 
al., 2010), which allows for a high-throughput production of proteins in vitro. 
HIV-1 PICs derived from infected cells are then treated with the human E3 
ubiquitin ligases, and subjected to the in vitro integration assay in microtiter 
plates. Finally, the level of integration was measured by qPCR to efficiently 
identify cellular proteins that potentially promote or impede PIC activity in 
vitro. 
Upon the identification of candidate proteins that can substantially 
influence PIC activity in vitro, further biochemical and cell-based studies were 
carried out to validate the genuine effects of these proteins on PIC function. 
The secondary aim was hence to elucidate in partial a plausible mechanism by 
which the candidate protein modulates HIV-1 PIC activity. Consequently, 
these candidate proteins would serve as useful targets in the restriction of 
HIV-1 infection, and eventually direct the path for the development of new 






CHAPTER 2: MATERIALS AND METHODS 
2.1 Preparation of target DNA-coated microtiter plate  
Target DNA for the integration assay was prepared by linearizing 
pUC19 plasmid (New England Biolabs) with EcoRI. One microgram of the 
linearized DNA was suspended in 20 mM 1-methyl-imidazole (1-MI), pH 7.0 
(Sigma) and 200 mM 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide 
(Sigma), and added to each well of the 96-well Covalink amine-coated plate 
(Corning) that had been pre-washed 3 times with 20 mM 1-MI, pH 7.0. The 
plate was sealed and incubated at 50°C for 3 h. Subsequently, plate wells were 
washed 5 times with wash Buffer A (1 M NaCl, 20 mM HEPES, pH7.4, 1% 
SDS, 10 mM EDTA) at 65°C (the third wash was done at 68°C for 20 mins), 
and another 5 times with wash Buffer K (150 mM KCl, 20 mM HEPES, 
pH7.4, 5 mM MgCl2). The wells were then incubated in Buffer K with 10 mM 
citracodonic anhydride (Sigma) for 30 min, after which the buffer was 
replaced with Buffer K containing 100 μg/ml tRNA (Sigma) and 0.2% bovine 
albumin serum (BSA). The plate was stored at 4°C until use. 
2.2 Preparation of HIV-1 PIC  
2.2.1 Cell culture  
Human embryonic kidney (HEK) 293T cell line was grown in 
Dulbecco's modifed Eagle’s medium (DMEM) containing high glucose 
(Invitrogen) supplemented with 100 units/ml penicillin, 100 μg/ml 
streptomycin, and 10% fetal calf serum (FCS, Gibco) at 37°C under a 95% 
air/5% CO2 atmosphere.  
2.2.2 HIV-1 vector production 
For the production of HIV-1-derived lentiviral vectors, 2×106 of 293T 
cells on a 10 cm dishes were transfected using calcium phosphate with 38.25 
μg of HIV-1-vector plasmid (pEV731) expressing Tat and EGFP under the 
control of the LTR (Jordan et al., 2001), 27 μg of HIV-1 Gag-Pol-expressing 
plasmid (pMDLg/pRRE), 11.25 μg of HIV-1 Rev-expressing plasmid (pRSV-
Rev) and 11.25 μg of the vesicular stomatitis virus G (VSV-G) envelope 
protein-expressing plasmid (pMD.G). The medium was replaced 16 h after 
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transfection, and supernatants containing infectious viral particles were 
harvested 48 h after transfection. Supernatant of transfected cells was then 
filtered through 0.45μm syringe filter and treated with 400 U/ml DNase1 
(NEB) for 1 h at 37°C to remove untransfected plasmid DNA.   
2.2.3 HIV-1 PIC isolation 
DNase-treated supernatant containing infectious HIV-1 vector (10 ml) 
was added to 3.3×106 293T cells in a 10 cm dish. Infection was carried out at a 
multiplicity of infection (MOI) of approximately 10. After 7 h of infection, 
cells were trypsinized and washed 3 times with Buffer K before permeabilized 
in 500 μl Buffer K with 1 mM dithiothreitol (DTT), 20 μg/ml approtinin 
(Sigma) and 0.025% digitonin (Sigma) for 5 min on ice. Lysates were 
centrifuged at 1,500 xg for 4 min and the supernatant was centrifuged again at 
16,000 g for 1 min. The final supernatant containing cytoplasmic PICs was 
mixed with 100 μl of Buffer K containing 40% sucrose and stored at -80°C 
until use. 
2.3 Production of human E3 ubiquitin ligase library 
2.3.1 Cloning of human E3 ubiquitin ligase cDNAs 
Open reading frame (ORF) of cDNAs from a human E3 ubiquitin 
ligase library (kindly provided from Dr. Endo and Dr. Sawasaki, Ehime 
University, Japan) were amplified by polymerase chain reaction (PCR) using 
sense primers uniquely designed for each clone beginning with the S1 
sequence (5’-CCACCCACCACCACCAATG-3’) followed by 15 bp of the 
ORF-specific sequence, and antisense primers AODA2306, AODS or 
pDONR221_1stA4080 (Table A1.1), depending on the vector backbone 
containing the entry clone according to CellFree Sciences’s protocol. The 25 
μl PCR reaction mix contained 100 nM each of both primers, 2.5 μl of the 
Escherichia coli (E. coli) culture containing the template clone, 0.2 mM 
dNTPs and 0.25 U/μl of blend-taq polymerase (Toyobo). The cycling method 
was 1 cycle of 94°C for 2 min, 30 cycles of 94°C for 30 s, 55°C for 30 s and 
72°C for 5min, followed by 1 cycle of 72°C for 5 min.  
A second PCR was performed using 1 μl of the previous product in a 
50 μl reaction mix containing 100 nM Spu primer (Table A1.1), 100 nM of the 
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respective antisense primer AODA2303, AODS-3 or pDONR221_2ndA4035 
(Table A2.1; CellFree Sciences protocol), 0.2 mM dNTPs, 0.25 U/μl of blend-
taq polymerase and 0.5 μl of glutathione-S transferase (GST)-tag that had been 
amplified from GST-TEV-MCS plasmid (CellFree Sciences). The cycling 
method was 1 cycle of 94°C for 2 min, 5 cycles of 94°C for 30 s, 55°C for 1 
min and 72°C for 5 min, 30 cycles of 94°C for 30s, 60°C for 30s and 72°C for 
5min, followed by 72°C for 5 min.  
2.3.2 Wheat germ cell-free expression of human E3 ubiquitin ligases 
The expression of human E3 ubiquitin ligases as GST-fused proteins 
was performed using the GenDecoder 1000 protein synthesizer (CellFree 
Sciences) which can produce up to 384 proteins in a single run using 96-well 
plates according to manufacturer’s protocol. In vitro transcription (IVT) 
required 1 μl of second PCR product for each E3 clone, 1.5x transcription 
buffer (120 mM HEPES-KOH, pH7.8, 24 mM magnesium acetate, 3 mM 
spermidine, 15 mM DTT), 3.75 mM NTP mix, 1.2 U/µl of RNase inhibitor 
and 2.4 U/µl of SP6 RNA polymerase (CellFree Sciences) to a total reaction 
volume of 20 µl. After 4 h of incubation at 37°C, the mRNA product was 
precipitated using 360 mM of ammonium acetate in 100% ethanol. The 
translation process was carried out through a bilayer diffusion method as 
described by ENDEXT® technology (CellFree Sciences). The mRNA pellets 
were resuspended in 25 µl of the lower layer of the translation mix containing 
6.25 µl of WEPRO1240G, 0.2 µg/µl of creatine kinase and 1x SUB-AMIX® 
(30 mM HEPES-KOH, pH 8.0, 1.2 mM ATP, 0.25 mM GTP, 16 mM creatine 
phosphate, 4 mM DTT, 0.4 mM spermidine, 0.3 mM each of the 20 amino 
acids, 2.7 mM magnesium acetate, and 100 mM potassium acetate). The upper 
layer of the translation reaction contains 125 µl of 1x SUB-AMIX®, and was 
first added to the reaction well, before the lower layer was carefully ejected to 
the bottom of the plate. The bilayer mixture was incubated at 16°C for 20 h. 
The whole process was fully automated in GenDecoder 1000 protein 
synthesizer and after 24 h of incubation, 150 µl of crude protein in each well 
was collected. Two reactions to yield a total of 300 µl of crude protein were 




2.3.3 Purification of human E3 ubiqitin ligases 
Purification of proteins was carried out using GST MultiTrap FF (GE 
Healthcare) in a 96-well format. In the binding reaction, 300 μl of crude 
protein was mized with 350 μl of Buffer P (10 mM sodium phosphate, pH 7.4, 
500 mM NaCl) and 50 μl of Glutathione Sepharose 4 Fast Flow beads (GE 
Healthcare) pre-equilibrated to 50% slurry with Buffer P, and then incubated 
at 4°C with rotation for 1 h. The protein-beads mixture was transferred to the 
96-well filter via centrifugation at 100 xg for 4 min and washed with 250 μl of 
Buffer P for 4 times, each time with centrifugation at 500 xg for 2 min. Sixty 
microliter of elution buffer (50 mM Tris-HCl, pH 8.0, 10% glycerol, 1 mM 
DTT, 5 mM EDTA, 10 mM reduced glutathione [Sigma]) was then added to 
the protein-beads mixture, and the reaction was incubated at 4°C for 30 min. 
Eluted proteins were collected in a 96-well plate by centrifugation at 500 xg 
for 2 min.  
To check the expression and purity of each protein. the eluates were 
denatured in sodium dodecyl sulfate (SDS)-sample buffer (12.5 mM Tris-HCl, 
pH 6.8, 0.5% SDS, 2.5% glycerol, 6.25 µg/ml bromophenol blue, 1.5% beta-
mercaptoethanol [-ME]) and separated in a 10% SDS-PAGE gel, followed 
by coomassie brilliant blue (CBB) staining (Wako Pure Chemical Industries). 
For proteins that could not be visualized from CBB staining, proteins resolved 
by SDS-PAGE gels were transferred to Immobilion-P transfer membrane 
(Millipore), and immunoblotting analysis was performed using anti-GST 
mouse monoclonal IgG (Santa Cruz), followed by horseradish peroxidase 
(HRP)-conjugated anti-mouse IgG (Cell Signaling Technology). Proteins were 
detected with Western Lightning ECL reagent (PerkinElmer) via Image-Quant 








2.4 Screening of human E3 ubiquitin ligases using in vitro PIC integration 
assay 
2.4.1 Microtiter plate-based assay  
Five microliter of each purified E3 ubiquitin ligase was added to 25 μl 
of PIC in a 96-well plate and incubated at 37°C for 1 h. Microtitter plate 
immobilized with target DNA was rinsed 5 times with Buffer K and tapped 
dry, and 30 μl of PIC-protein mixture was added into each well with 30 μl of 
2x integration mix (20 mM HEPES-NaOH, 10 mM MgCl2, 150 mM KCl, 20 
mM DTT, 200 μg/ml BSA, 30% glycerol). Reactions were incubated at 37°C 
for 30 min to allow integration. To terminate the reaction, proteinase K 
solution (5 mg/ml proteinase K [NEB] and 5 % SDS) was subsequently added 
and the plate was incubated at 37°C for another 1 h to inactivate the PIC. To 
remove unreacted viral DNA, wells were washed 5 times with wash Buffer A 
at 65°C (the third wash was done at 68°C for 20 min), and another 5 times 
with wash Buffer K, as described above. DNA were eluted from each plate by 
incubating with 30 μl of 0.04 N NaOH at 50°C for 10 min before 
neutralizating with 30 μl 0.04N HCl and 50 mM HEPES, pH7.5 and collected.  
2.4.2 Quantification of integrated products by PCR 
 For qPCR, 5 μl of eluted DNA product from each sample well was 
added to 20 μl of PCR reaction mix containing 0.3 μM of each HIV-1 DNA 
specific primer (forward [M667]: 5’-GGCTAACTAGGGAACCCACTG-3’ 
and reverse [AA55]: 5’-CTGCTAGAGATTTTCCACACTGAC-3’ [Suzuki et 
al., Virus Genes, 2003]), 0.2 μM HIV-1 DNA specific fluorescent probe (5’-
FAM-TAGTGTGTGCCCGTCTGTTGT-TAMRA-3’ [Suzuki et al., Virus 
Genes, 2003]) and 10 μl TaqMan® Gene Expression Master Mix (Applied 
Biosystems). Fluorescence-monitored qPCR were performed on an ABI Prism 
7500 (Applied Biosystems) with cycling method 2 cycles of 50°C for 2 min 
and 95°C for 10 min, and 40 cycles of 95°C for 15 s and 60°C for 1 min. 
qPCR data was analyzed using the ABI 7500 software v2.0.6. The amount of 
DNA quantified for each sample is calculated as a percentage that of the 




2.5 Evaluation of candidate E3 ligases using from E.coli-derived 
recombinant proteins 
2.5.1 Construction of plasmid DNA for bacterial protein expression 
 Unique forward and reverse primers (Table A1.2) for each candidate 
protein were phosphorylated with T4 polynucleotide kinase (NEB) and used to 
amplify the gene of interest. The 50 μl PCR reaction, which contained 5 μl of 
plasmid DNA encoding each gene, 100 nM each of the two phosphorylated 
primers, 1x KOD buffer, 0.2 mM dNTPs, 1 mM MgSO4, and 1U KOD plus 
(Toyobo), ran at a cycling method 1 cycle of 94°C for 2 min, 35 cycles of 
94°C for 30 s, 60 °C for 30 s and 68°C for 1 min (2 min for RNF25), and 1 
cycle of 68°C for 10 min. Bacterial expression vector pGEX-2T (GE 
Healthcare) was linearized at the SmaI site and the blunt ends were 
dephosphorylated using Calf intestinal alkaline phosphatase (NEB) and ligated 
with PCR product of each candidate protein using T4 DNA ligase (NEB). 
2.5.2 E.coli expression of candidate proteins  
 pGEX-2T vector containing the gene of interest for the candidate 
proteins were transformed into E. coli BL21(DE3) competent cells 
respectively and grown in LB medium supplemented with ampicillin at 37°C 
until an optical density at 600 nm (OD600) of 0.5, followed by induction with 
1 mM of isopropyl-beta-D-thio-galactopyranoside (IPTG) for 5 hours at 37°C. 
Bacteria cells were then harvested by centrifugation, and the pellet was 
dissolved in resuspension buffer (50 mM Tris-HCl, pH7.5, 150 mM NaCl, 1 
mM EDTA) to be stored at -80°C. IPTG-induced protein expression was 
checked by SDS-PAGE and CBB staining.  
For protein extraction, a lysis buffer (50 mM Tris-HCl, pH7.5, 150 
mM NaCl, 5 mM EDTA, 0.028%β-ME and 0.4 mg/ml lysozyme [Sigma]) was 
added to the E. coli suspension, and the mixture was incubated at 4°C with 
rotation for 1 h until the suspension become viscous. The cells were lysed 
through sonication on ice and centrifuged at 9,500 xg for 30 min to clear the 
unwanted cellular debris. Finally, supernatant containing the soluble candidate 
protein was collected. 
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2.5.3 Purification of GST-tagged candidate proteins from E.coli 
expression 
 Bacterially expressed proteins were affinity purified using fast protein 
liquid chromatography (FPLC). The homogenized supernatant was repeatedly 
loaded onto a 5 ml Glutathione Sepharose 4B column (GE Healthcare) 
equilibrated with Buffer A (50 mM Tris-HCL, pH 8.0, 500 mM NaCl, 10% 
glycerol and 5 mM DTT) for 1 h at the rate of 1 ml/min to ensure maximal 
protein binding. Proteins were then eluted from the column with Buffer A 
containing 15 mM reduced glutathione. Eluted fractions were checked by 
CBB staining of the SDS-PAGE gel and fractions containing protein of the 
correct size were pooled for gel filtration chromatography. Size exclusion 
purification was performed using a Sephadex 200 10/300 GL column (GE 
Healthcare) where the proteins were desalted and subsequently eluted in 
Buffer A.  Separated fractions were again run on SDS-PAGE and checked by 
CBB staining to pool concentrated purified products corresponding to the 
correct size of the candidate protein. Protein concentration was determined by 
Bradford method (Bio-Rad) using BSA as a protein standard. 
2.5.4 Microtiter plate-based assay using GST-tagged candidate proteins 
from E.coli expression 
5 μl of 60 nM and 6 nM of each candidate protein was respectively 
incubated with 25 μl of PIC for 1 h at 37°C before addition to microtiter plate 
for in vitro PIC integration assay. The subsequent steps of the PIC assay and 
qPCR, as well as method of data analysis are similar to that described 







2.6 Production of RFPL3 mutant proteins 
2.6.1 Expression of RFPL3 mutants using wheat germ cell-free technology 
 Amplification of cDNAs encoding GST-fused full-length RFPL3 
(GST-RFPL3 FL) and its N-terminal deletion mutants (GST-RFPL3 Δ36, 
GST-RFPL3 Δ98 and GST-RFPL3 Δ146) by PCR was performed as described 
in 2.3.1 using S1primer containing unique sequence of each mutant (Table 
A1.3) and antisense primer pDONR221 (Table A1.1). Cell-free expression of 
proteins was performed manually, with the same reaction materials and 
procedure similar to that described in 2.3.2. Transcription was performed to a 
total reaction volume of 2 ml and incubated at 37°C for more than 3 h. The 
mRNA product was then checked via gel electrophoresis on 1% agarose gel 
before proceeding with translation reaction on 6-well plate at 16°C for 20 h 
using a robotic protein synthesizer, Protemist DTII (CellFree Sciences). 
2.6.2 Purification of RFPL3 mutant proteins and PIC integration assay 
 Batch purification was also performed using Protemist DTII according 
to manufacturer’s instructions. Glutathione Sepharose 4 Fast Flow beads pre-
equilibrated to 50% slurry with Buffer P was used to bind the GST-tagged 
proteins and the proteins were finally eluted with elution buffer (50 mM Tris-
HCl, pH 8.0, 10% glycerol, 1 mM DTT, 5 mM EDTA and 10 mM reduced 
glutathione). The affinity purified proteins were further purified via FPLC 
using a 5 ml HiTrap esalting column (GE healthcare) using Buffer A (50 mM 
Tris-HCL, pH 8.0, 500 mM NaCl, 10% glycerol, 5 mM DTT). Protein 
concentration was determined by Bradford method using BSA as a protein 
standard. Purity of the proteins was checked by CBB staining following SDS-
PAGE analysis. Purified proteins were used for PIC integration assay as 






2.7 Other in vitro experiments involving RFPL3 
2.7.1 Gel-shift assay  
pUC19 vector was digested at the ScaI and NdeI sites to generate a 691 
bp fragment, which served as the DNA substrate. Two hundred fifty picomolar 
substrate DNA was incubated with 25 nM of GST-FRPL3 or GST-DHFR in 
10 μl of binding buffer (20 mM HEPES, pH7.5, 1 mM DTT, 100 ng/ml BSA) 
at 30°C for 1 h. Subsequently, the mixtures were separated by agarose gel 
electrophoresis with a 0.5% agarose gel in TAE buffer and blotted to a 
GeneScreen Plus membrane (PerkinElmer Life Sciences). Southern blotting 
analysis was performed using Gene Images AlkPhos Direct labelling and 
detection system (GE Heathcare) according to manufacturer’s protocol, and 
DNA was detected by an AP-labelled substrate DNA probe, followed by 
visualization via Image-Quant LAS4000 mini chemiluminescent image 
analyzer (GE Healthcare). 
2.7.2 In vitro PIC integration assay with MoMLV PIC  
Mouse embryo fibroblast cell line, NIH3T3, and MoMLV-producing 
cell line, clone 4 cells (Fujiwara and Mizuuchi, 1988) were grown in the same 
culture conditions as that for 293T described in 2.2.1. To produce MoMLV 
PICs, 2x106 of NIH3T3 cells were co-cultured with 1x106 of clone 4 cells in a 
10 cm dish for 16 h. The PIC-containing cytoplasmic fraction was extracted as 
described in 2.2.3 and stored at -80°C. In vitro PIC integration assay was 
carried out in the same way as described in 2.4 to assess the effect of RFPL3 
on the integration activity of MoMLV PIC per se.  
2.7.3 AlphaScreen interaction assay with recombinant HIV-1 IN 
A pET15b vector encoding full-length His-taggeed HIV-1 IN (Dr 
Robert Craigie, NIH, USA) was transformed into E.coli BL21 competent cells 
and grown at 37°C until an OD600 of 0.8, followed by induction with 0.4 mM 
IPTG for 3 h at 37°C. Cells were lysed as previously described in section 
2.5.2, using a lysis buffer containing 1 M NaCl, 2 mM β-ME, 0.4 mg/ml 
lysozyme and 20mM HEPES, pH 7.5. Purification was done through FPLC 
using a 5 ml HiTrap Nickel chelating High-performance column (GE 
Healthcare) pre-equilibrated in Buffer A (20 nM HEPES, pH 7.5, 1 M NaCl, 
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10% glycerol, 2 mM β-ME. Proteins were eluted with buffer containing 20 
mM HEPES, pH7.5, 1 M NaCl and 10% glycerol through an imidazole 
gradient of 20 mM to 500 mM. This was followed by gel filtration using 
elution buffer containing 20 mM HEPES, pH 7.5, 1 M NaCl, 10% glycerol 
and 5 mM DTT.  
PCR product encoding the LEDGF-IBD (residues 347-471) was 
amplified and cloned into a pGEX-2T vector through the EcoNI and XmalI 
restriction sites to generate plasmid for transformation. Protein production 
using E. coli and FPLC purification methods for GST-LEDGF were similar to 
that previously described in Section 2.5.2 and 2.5.3.  
The DHFR gene of interest was amplified and His-tag added to the 
PCR product for protein production of His-DHFR through the wheat germ 
cell-free system according to CellFree Sciences protocol as described in 
Section 2.3.1 and 2.7.1 (ENDEXT© Technology). Batch purification was 
performed as described in Section 2.7.2, using nickel-high performance beads 
(GE Healthcare), wash buffer (20 mM Tris-HCl, pH 7.5, 500 mM NaCl, 40 
mM imidazole, 10% glycerol), elution buffer (20 mM Tris-HCl, pH 7.5, 500 
mM NaCl, 500 mM imidazole, 10% glycerol), and solution A (600mM 
imidazole, pH 8.0). All purified proteins were checked via CBB staining. 
In vitro interaction assay through AlphaScreen technology was 
performed using a 384-well OptiPlate (PerkinElmer). 100 nM of His-protein 
and 100 nM of GST-protein were added to a binding mixture containing 
AlphaScreen buffer (25 mM HEPES, pH 7.5, 1 mM DTT, 2 mM MgCl2, 0.1% 
BSA) to a total volume of 15 µl. The binding reaction was performed at room 
temperature for 1 hour. Subsequently, 10 µl of detection mixture was added 
under dark conditions and the total reaction was incubated for another hour at 
room temperature in the dark. GST-protein:His-protein interaction was 
detected using a mixture containing 0.1 μl Nickel Chelate acceptor beads, and 
0.1 μl GSH donor beads (AlphaScreen detection kit, PerkinElmer) suspended 
in 1x AlphaScreen buffer.  
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2.8 Cell-based studies  
2.8.1 Construction of lentiviral vectors expressing candidate genes 
Using the unique primers designed (Table A2.2), the ORF of each candidate 
protein was amplified and first inserted into a p3xFLAG-CMV14 vector that 
had been digested with EcoRV (refer to protocol described in 2.5.1). An 
additional PCR was performed using a common set of forward 
(5’GGGGACAAGTTTGTACAAAAAAGCAGGCTgcgaattcatcgatagatctgat-3) and reverse 
(5’GGGGACCACTTTGTACAAGAAAGCTGGGTCctacttgtcatcgtcatccttg-3’) primers to 
amplify the region covering the ORF of p3xFLAG-CMV14 vector (small 
letters), with the addition of Gateway entry sequences (CAPS) (Hartley et al., 
2000).  
The amplified C’-terminal FLAG-tagged ORF fragments were each 
inserted into the gateway entry vector, pDONR221, through a BP reaction 
using Gateway Technology® according to manufacturer’s protocol 
(Invitrogen). After sequence confirmation, individual candidate protein genes 
in pDONR221 were transferred to Gateway-compatible lentiviral vector, 
pYK005C-BLAR (Kawano et al., 2004) by a LR reaction (Invitrogen). 
2.8.2 Establishment of cell-lines stably expressing candidate proteins  
  To produce infectious lentiviral vectors expressing FLAG-tagged 
candidate gene, 8×105 of 293T cells on 6 cm dish were transfected with 7 μg 
of lentiviral vector plasmid, 5 μg of pMDLg/pRRE, 2 μg of pRSV-Rev and 2 
μg of pMD.G by calcium phosphate transfection method, following protocol 
in 2.2.2. Two days after transfection, culture supernatant was filtered and 
added to 5×105 of 293T cells on 10 cm dish. Transduced cells were then 
cultured in the presence of 10 μg/ml of blasticidin (Invitrogen) to select the 
cells with successful recombination and integration of candidate gene from the 
lentiviral vector into host chromosome. The blasticidin medium was changed 
every 3 days and cells were repeatedly passaged, upon 80% confluency for 
one week. Protein expression in blasticidin-resistant stable cell line was 
checked by lysing the cells in RIPA buffer (25 mM Tris-HCl, pH7.6, 150 mM 
NaCl, 1% NP40, 1% sodium deoxycholate, 0.1% SDS). The lysate supernatant 
was denatured in SDS-PAGE buffer and resolved on a 12% SDS-PAGE gel to 
proceed with immunoblotting using HRP-conjugated anti-FLAG mouse 
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monoclonal IgG (Cell Signaling Technology), followed by detection with 
western ECL reagents via Image-Quant LAS4000 mini chemiluminescent 
image analyzer.  
2.8.3 Immunofluorescence analysis 
Immunofluorescent analysis (IFA) of FLAG-tagged proteins was 
carried out on the stable cell-lines grown in Lab-Tek II 8-well chamber slides 
(Thermo). Fifty-thousand cells that had been seeded a day before staining 
were washed twice with PBS and fixed with 4% paraformaldehyde for 30 min 
at room temperature, followed by 2 washes again with PBS. Fixed cells were 
permeabilized with 0.1% Triton X-100 in PBS for 10 min and blocked in PBS 
containing 10% FBS and 5% BSA for 30 min at room temperature. The cells 
were then stained with primary antibody, anti-FLAG rabbit monoclonal IgG 
(Sigma), for 1 h at room temperature, followed by secondary antibody, Alexa 
Fluor 488-conjugated goat anti-rabbit IgG (Invitrogen), for another hour at 
room temperature under dark conditions. Slides were treated with ProLong 
Gold antifade mounting agent containing 4,6-diamidino-2-phenylindole 
(DAPI, Molecular Probes), which also counterstained cell nuclei. Nail varnish 
was used to seal the edges before the slides were observed under a 40X 
Olympus IX81 fluorescence microscope. Images were captured with the 
CellSens Dimension software (Olympus). 	
2.8.4 Immunoprecipitation analysis of HIV-1 PIC 
 PIC from 293T cells expressing FLAG-tagged RFPL3 and DHFR were 
isolated using the same protocol previously described in 2.2.3. One hundred 
twenty five microliter of PIC samples were mixed with 250 μl of Buffer C (20 
mM HEPES-NaOH, pH 7.4, 5 mM MgCl2, 150 mM KCl, 6 mM EDTA, 
0.04% BSA, 0.1% NP40, protease inhibitors). After keeping 75 μl of the 
mixture as input fraction, 300 μl of the mixture was incubated with 10 μg of 
anti-FLAG mouse monoclonal IgG (M2, Sigma) at 4°C for 2 h with rotation, 
followed by addition of 30 μl of protein A/G agarose beads (Santa Cruz) and 
another 2 h incubation at 4°C with rotation. The immune complex was washed 
three times with 500 l of Buffer C, and then deproteinized by proteinase K 
and SDS. Viral DNA was recovered from phenol/chloroform extraction and 
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ethanol precipitation, followed by resuspension in 10 μl Tris-EDTA buffer 
containing 20 μg/ml RNase A (QIAGEN). Detection of precipitated DNA was 
done via PCR using 2 μl of sample, 0.3 μM of AA55 and M667 primers, 1x 
KOD buffer, 0.2 mM dNTPs, 1.5 mM MgSO4 and 0.5U KOD plus 
(TOYOBO) in a 25 μl reaction volume. Cycling condition was set at 1 cycle 
of 94°C for 2 min, 28 cycles of 98°C for 10 s, 60°C for 30 s and 68°C for 1 
min, and 1 cycle of 68°C for 10 min. Ten microliter of PCR product was 
subjected to gel electrophoresis using a 1.5% agarose gel and Trisacetate-
EDTA (TAE) buffer. The gel was stained with ethidium bromide and imaged 
under UV light in a transilluminator (Insta BioAnalytik). 
2.8.5 HIV-Luciferase assay on RFPL3-expressing 293T cells 
For the production of HIV-1-derived lentiviral vectors expressing 
luciferase, 1×105 293T cells were seeded in a 12-well plate and transfected 
using calcium phosphate with 17 μg of pYK005-Luciferase plasmid (Kawano 
et al., 2004), 12 μg of pMDLg/pRRE, 5 μg of pRSV-Rev and 5 μg of pMD.G. 
The cells were cultured as described in Section 2.2.2 and the supernatant 
harvested 48 h after transfection. The CA level of the viral supernatant was 
measured with HIV-1 p24 antigen enzyme-linked immunosorbent assay 
(ELISA) kit (Zetrometrix). 10 ng p24 virus was subsequently inoculated to 
RPL3 or DHFR-expressing stable cell lines previously seeded in 12-well plate 
at 1×105/well density one day before infection. At 48 h post infection, cells 
were washed with PBS once and lysed with 200 μl of M-PER Mammalian 
Protein Extraction Reagent (Thermo) at room temperature for 10 min. The 
supernatant was subsequently centrifuged at 10,000 rpm for 5 min before 
being used for luciferase assay using the Renilla Luciferase Glow Assay Kit 
(Thermo). Luminescence level was detected using the Synergy H1 Hybrid 
Multi-Mode Microplate Reader. Protein concentration of each sample 
supernatant was quantified using the Bradford kit (Bio-Rad) to normalize the 
luciferase activity measured.  
In this study, all experiments involving infectious HIV-1-derived 
lentiviral vector were performed in an enhanced BSL-2 facility of Department 
of Microbiology with BSL-3 practice under supervision of Dr. Youichi Suzuki 
who is a certified HIV-1 researcher of our laboratory. 
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CHAPTER 3: RESULTS 
3.1 Establishment of a novel in vitro microtiter plate-based PIC 
integration assay for the identificaiton of host modulators 
In order to efficiently identify cellular factors that modulate the 
function of HIV-1 PIC, we developed a rapid in vitro integration assay system 
for high-throughput screening study of the PIC. Firstly, pUC19-derived 
linearized target DNA (2.9 kb) was covalently immobilized on a 96-well 
covalink plate via carbodiimide condensation. HIV-1 PICs were isolated as 
crude cytoplasmic extract from freshly infected 293T cells using a weak 
detergent, digitonin. The PIC samples were added to the coated wells and 
incubated to allow for integration of the viral DNA from the PIC into the 
immobilized target DNA. The PICs were then deproteinized and the wells 
washed to remove the unintegrated viral DNA and protein components. Target 
DNA was released from each well and the amount of integrated DNA was 
quantified through fluorescent qPCR using specific primers that recognize the 
R-U5 region of the LTRs of HIV-1 DNA (Figure 3.1.1). 
Specificity of the assay was first examined using active PICs and 
inactivated PICs that had been treated with proteinase K and SDS as negative 
control. The mean amount of viral DNA detected from reactions incubated 
with active PIC was 5957.6 ± 4.5% copies, which was about 34 times higher 
than that of the mean DNA detected in inactivated PIC wells (176.6 ± 0.2% 
copies, p < 0.001, Figure 3.1.2). This confirms that the assay platform using 
targeted DNA-coated microtiter plate can specifically detect integrated viral 
DNA produced by enzymatically active PICs, thereby allowing the effective 


















Figure 3.1.1 Schematic diagram of microtiter plate-based PIC integration assay in vitro. 
Target DNA was immobilized on the bottom of the amine-coated well through carbodiimide 
condensation (Step 1). PIC samples were added to the wells and incubated for 30 min at 37°C 
(Step 2) before the deproteinization and removal of unintegrated DNA and proteins (Step 3). 
Target DNA were released upon NaOH treatment (Step 4) and the integrated products were 
detected via qPCR using HIV-1 LTR specific primers AA55/M667 (Step 5).  
 
 
Figure 3.1.2 Quantification of integrated HIV-1 DNA by microtiter plate-based PIC 
assay.  25 μl of PIC was added to each well of the microtitier plate containing 2x integration 
buffer and incubated for 30 min, after which the PIC sample was inactivated using proteinase 
K/SDS solution. Wells were then washed and integrated products were released using NaOH 
to be quantified via qPCR. Inactivated PICs were pre-treated with proteinase K/SDS solution 
before being subjected to the microtiter plate-based PIC assay. The experiment was done in 






















Specificity of the microtiter plate-based integration assay was further 
evaluated using two proteins with known effects on PIC activity, namely BAF 
and VRK, at different concentrations. BAF is a component of the PIC and was 
found to enhance authentic integration by preventing autointegration of the 
viral DNA (Lee and Craigie, 1998). On the other hand, VRK abrogates the 
effect of BAF by phosphorylating the latter, causing its dissociation from the 
PIC, inhibiting integration activity (Suzuki et al., 2010).  
PIC samples were initially treated with GST-tagged BAF and VRK 
(Figure 3.1.3) at various concentrations (BAF: 10 and 100 nM; VRK: 20, 100 
and 500 nM), and then incubated in the target DNA-immobilized microtiter 
plate wells to allow for integration. A control protein, GST, was also included 
at various concentrations, and the amount of integrated product yield for both 
GST-BAF and GST-VRK treatments were expressed as a percentage that of 
the GST control protein treatment at the respective concentration. Results 
revealed concentration-dependent enhancing (GST-BAF) and inhibiting (GST-
VRK) effects of the two proteins on PIC activity (Figure 3.1.4). Treating PIC 
with 10 nM of GST-BAF approximately increased the yield of integrated 
products to 2-fold that of GST control protein at the same concentration, 
whilst at 100 nM, PIC activity was 3-fold that of the control protein. Similarly, 
inhibition effect by VRK was clearly dependent on the concentration of 
protein, although the effect seemed to have reached saturation towards higher 
concentrations i.e. 40% inhibition at 20 nM, followed by 70% inhibition at 
100 nM, and 85% inhibition at 500 nM. Taken together, these data indeed 
supported the ability of the assay to specifically detect proteins affecting HIV-





Figure 3.1.3 Preparation of GST-tagged BAF and 
VRK. GST-BAF and GST-VRK were derived from 
E.coli production and purified through FPLC using 5 ml 
Glutathione Sepharose 4B column. Purity of proteins was 


























































Figure 3.1.4 Modulation of PIC integration activity by BAF and VRK in vitro. (A) GST-
BAF was tested at increasing concentrations of 10 nM and 100 nM (B) GST-VRK was tested 
at increasing concentrations of 20 nM, 100 nM and 500 nM. The amount of integrated 










 In order to demonstrate the suitability of the PIC assay for a high-
throughput setting, the Z-factor of the newly developed assay was assessed. 
The Z-factor is a measure of the distance between the standard deviation for 
the positive (active PIC) and negative (inactivated PIC) controls, and is often a 
characteristic parameter to determine the quality of an assay for high-
throughput screening studies (Zhang et al., 1999). The Z-factor was calculated 
to be 0.56 (Figure 3.1.5), indicating that the PIC assay is a robust and reliable 



















Figure 3.1.5 Assessment of PIC assay by Z-factor. Integrated products from 8 wells 
incubated with active PICs were quantified, constituting the positive data points. Inactive PICs 
were also incubated in 8 other wells and the integrated products were subsequently quantified 
to constitute the background data points.  
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3.2 Production of human E3 ubiquitin ligases by wheat germ cell-free 
system 
 In order to generate a library of proteins, wheat germ cell-free protein 
synthesis system had been adopted using a GenDecoder 1000 machine 
(CellFree Sciences). The machine allows in vitro transcription and translation 
processes to be fully automated, producing up to 384 proteins per run in a 96-
well plate format using Gateway entry plasmid DNAs encoding ORF of gene-
of-interest as templates. A total of 200 human E3 ubiquitin ligases have been 
transferred into gateway entry vectors for cloning. The clones were separated 
into two batches of production (referred as Batch A and B) to allow ease of 
handling. The first round of cloning required S1 forward primer unique to the 
ORF sequence of each clone and a reverse primer specific to the entry vector 
(CellFree Sciences). One hundred eighty four 1st PCR products were 
successfully generated from the first round of PCR. This was followed by a 
second round of PCR, which adopted a split primer process to add the SP6 
promoter (SPU primer) and GST tag sequences to 5’ end of each ORF 
fragment for protein synthesis. The second round of PCR generated 170 
cDNA templates with the correct number of bases when checked via gel 





Figure 3.2.1 Gel electrophoresis of 2nd PCR products. 1 μl of each PCR product was loaded 
onto a 1% agarose gel in TAE buffer for gel electrophoresis, and stained with ethidium 
bromide to be imaged under UV light in a transilluminator. Clone numbers are labeled in 
yellow at the top of each lane while clones without a visible band of the right size are labeled 
in red. (A) 92/96 2nd PCR products were generated from the first batch of cloning (Batch A). 
(B) 78/88 2nd PCR products were generated from the second batch of cloning (Batch B). 
 
  
Each batch of PCR products was used to produce total 300 μl of crude 
protein solution per clone. The GST-tagged crude proteins were then purified 
using Glutathione Sepharose Fast Flow in 96-well plate format affinity 
purification modules. The purified proteins were eluted and their purity 
checked by SDS-PAGE and CBB staining analysis (Figure 3.2.2A). Proteins 
with low expression levels, which could not be visualized from CBB staining, 
were further checked by sensitive immunoblotting analysis using anti-GST 
antibody (Figure 3.2.2B). A total of 102 purified proteins can be visualized 
from CBB analysis alone, and additional 33 proteins were detected from 
immunoblotting. These 135 proteins were subsequently subjected to screening 






Figure 3.2.2 CBB staining and immunoblotting analysis to check on purity and 
expression of proteins produced. (A & B) Ten microliter of purified protein was denatured 
and resolved on a 10% SDS-PAGE gel for CBB staining A total of 102 proteins could be 
visualized from CBB staining alone (57/92 for Batch A and 45/78 for Batch B). (C) Five 
microliter of protein was used for immunoblotting via anti-GST mouse monoclonal antibody. 
A total of 33 proteins were detected (15 from Batch A and 18 from Batch B), bringing the 
total number of proteins available for screening to 135. Figures were representative data from 





3.3 A preliminary screen for HIV-1 PIC modulators using the human E3 
ubiquitin ligase library 
 A total of 135 purified E3 ubiquitin ligases were subjected to the in 
vitro microtiter plate-based PIC integration assay. Each protein was initially 
incubated with HIV-1 PIC samples for 1 h at 37°C. The mixtures were then 
added to each well of the target DNA-coated microtiter plate. Integration 
reaction was allowed to occur for 30 min at 37°C, after which the reactions 
were deproteinized, followed by two rounds of washing to remove the 
unintegrated viral DNA and protein components. Integrated viral DNA was 
released from the wells via treatment with NaOH, and after neutralization, 
detected by qPCR. Control proteins used in the screening included i) enhancer, 
GST-BAF, ii) inhibitor, GST-VRK, and iii) chemical IN inhibitor, elvitegravir 
(EVG, 1 μM), and iv) negative control, GST-tagged dihydrofolate reductase 
(GST-DHFR) to measure the background activity of PICs. Each batch of 
proteins was subjected to multiple rounds of screening, with the use of newly 
isolated PIC samples each time, and at least one round using a newly produced 
and purified batch of E3 ubiquitin ligases and control proteins.  
Figure 3.3.1 shows the screening results for the 72 proteins from Batch 
A in 4 rounds of screening, in which values were presented as a percentage of 
the copy number of integrated viral DNA detected when compared to GST-
DHFR-treated PICs (set as background level at 100%). A value greater than 
100% would indicate an enhancing effect of the protein on PIC activity, 
whereas a value less than 100% will indicate inhibition of integration activity. 
All data were arranged in descending order from proteins showing the highest 
activity to that with the lowest within the particular screen per se. After the 
first two rounds of screening (Figure 3.3.1A and B), 11 proteins that exhibited 
consistent effects on PIC activity, either enhancement or inhibition, were 
selected to carry out a third test (Figure 3.3.1D) using the same batch of 
purified proteins. Finally, all Batch A E3 ligases were produced for a second 
time and subjected to a final round of screening (Figure 3.3.1C) to confirm the 
effects on PIC activity. Four candidate proteins that consistently enhance or 
inhibit PIC activity in all rounds of screening were selected, including RFPL3 
as an enhancer, and RNF25, STUB1 and TRIM52 as inhibitors. 
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The 63 remaining E3 ubiquitin ligases from Batch B were subjected to 
3 rounds of preliminary screen (Figure 3.3.2). Again, candidate inhibitors were 
chosen based on the ability to inhibit PIC activity in all 3 replicates, namely 
MYLIP and RSPRY1. As quite a handful of proteins from Batch B exhibited 
enhancement profile in all 3 rounds of screening, in order to reduce the 
number of false positives, a more stringent rule was used to select potential 
enhancers, based on the scale of the enhancement i.e. proteins that enhance 
PIC activity by more than 2-fold that of GST-DHFR control in all 3 replicates. 



























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 3.3.1 Screening profile for Batch A E3 ubiquitin ligases. Newly isolated PICs were 
used for every new round of screening. Integrated viral DNA detected is presented as a 
percentage that of control protein GST-DHFR (100%), which is indicative of the modulation 
effect of the protein on PIC integration. (A and B) First two initial rounds of screening done 
with the same batch of purified E3 ubiquitin ligases and control proteins. (C) Another round 
of screening performed with newly produced and purified Batch A proteins. (D) Eleven 
proteins showing significant and consistent modulation on PIC activity were selected for a 
repeated screen to better confirm the results. RFPL3 (dark green) consistently enhanced PIC 



































































































Figure 3.3.2 Screening profile for Batch B E3 ubiquitin ligases. Freshly isolated PICs and 
newly produced proteins were used for every round of screening. Integrated viral DNA 
detected is presented as a percentage that of control protein GST-DHFR (100%), which is 
indicative of the modulation effect of the protein on PIC integration. (A), (B) and (C) are data 
from three different rounds of screening respectively. Potential enhancers (dark green) were 
chosen based on ability to enhance PIC activity by more than 2-fold that of control GST-
DHFR in all 3 rounds of screening. Potential inhibitors (red) were chosen based on ability to 
consistently inhibit PIC activity in all rounds of screening. Four candidate proteins were 




































3.4 Validation of candidate PIC modulators— effect of E. coli-produced 
candidate E3 ligases on PIC activity 
 Although a total of 8 candidate proteins were selected from the 
preliminary screen of the two batches of E3 ubiquitin ligases, validation 
studies were begun on the candidates identified in Batch A, namely RFPL3, 
RNF25, STUB1 and TRIM52. Firstly, in order to confirm the in vitro 
modulation effect on PIC activity by the candidates, a concentration-
dependent study was carried out using recombinant proteins derived from a 
different source. 
The ORF of the 4 candidate proteins were cloned into pGEX-2T 
bacterial expression vector and transformed into E. coli BL21 (DE3) 
competent cells. Expression of each GST-tagged candidate protein was 
induced upon addition of IPTG into the culture with incubation at 37°C for 5 
hours. The E. coli cells were then lysed to extract the supernatant. Purification 
of bacterial-derived proteins was done by affinity and subsequent size 
exclusion chromatographies. Purity of the proteins were checked via CBB 
staining (Figure 3.4A).  
The four proteins were then subjected to microtiter plate-based in vitro 
PIC integration assay using 1 and 10 nM of proteins. The amount of integrated 
DNA products at each concentration of the candidate protein was expressed as 
a percentage of control GST protein-treated PICs (set at 100%, Figure 3.4B). 
When HIV-1 PIC was incubated with 1 nM GST-RFPL3, the level of viral 
DNA detected was 35% ± 12.9% higher than that of GST control (p < 0.05). 
At 10 nM, the enhancement effect by GST-RFPL3 was increased further to 
170% ± 38.3% (p < 0.05). In comparison, enhancement by a positive control, 
GST-BAF, was rather similar to that observed for RFPL3, at 132% ± 9.9% (p 
< 0.05) and 168% ± 25.6% (p < 0.01) at 1 and 10 nM of BAF, respectively. 
This indicates that RFPL3 probably has bona fide PIC enhancing effect in 
vitro, which was of comparative strength to that of known cellular enhancer 
BAF. 
On the other hand, at 1 nM concentration of protein, none of the other 
candidate inhibitors (RNF25: 143% ± 26.1%; STUB1: 140% ± 22.0%; 
TRIM52: 143% ± 16.2%) showed a reduction in PIC activity, this was also the 
case for positive control for the inhibitors, GST-VRK, with a quantified 
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percentage of viral DNA copies at 114.5% ± 27.9%. This could suggest that 
such a low concentration of protein was insufficient to adequately reduce or 
abrogate PIC integration activity during the microtiter plate-based assay. A 
greater concentration of protein might be required for efficient inhibition since 
the PIC consists of many other cellular factors from the cytoplasmic fraction 
that contributes to the functional activity of PIC as a whole, possibly masking 
the PIC inhibiting effect of candidates added at low concentrations. True 
enough, at a higher concentration (10 nM), GST-VRK was able to exhibit its 
inhibiting ability, reducing PIC activity to 71.9% ± 16.0% that of GST control 
(p < 0.05). Out of the candidate proteins, only GST-RNF25 at 10 nM, reduced 
the amount of quantified viral DNA to 89.9% ± 16.3% below that of GST 
control. The reduction was however not statistically significant, with a p-value 
of 0.363. GST-STUB1 and GST-TRIM52 also did not exhibit any reduction in 
PIC activity even at 10 nM, with quantified percentages of 107.0% ± 12.7% 
and 108.0% ± 1.88%, respectively.  
From these data, the candidate inhibitors seemed to have minimal 
effect on PIC activity. There can be a possibility of insufficient amount of 
protein added, but this will indicate that the identified candidates were 
probably not as strong as VRK in their abrogation of PIC integration activity, 
since VRK could show a significant reduction at 10 nM but not the rest. It 
could also be that the inhibitors identified were probably false positives from 
the screening results. On the other hand, the results gave sufficient evidence to 









     
Figure 3.4 PIC assay with candidate proteins produced by E. coli. (A) Purification of 
recombinant proteins. Size of GST-tagged proteins, RFPL3: 58kDa, RNF25: 78kDa, STUB1: 
59kDa, TRIM52- 60kDa, control GST: 26 kDa. (B) Two different concentrations (1 and 10 
nM) of each protein were incubated with 25 μl of PIC respectively before addition to each 
well for in vitro integration assay. Quantified integrated products were displayed as a 
percentage that of GST control protein of the same concentration. The experiment was done in 




3.5 Characterization of RFPL3 as an in vitro enhancer of HIV-1 PIC 
3.5.1 Determination of the functional domain in RFPL3 essential to the 
enhancement of PIC activity in vitro  
 Upon the confirmation of a concentration-dependent enhancement 
effect of PIC activity by RFPL3 in Section 3.4, it is important to elucidate the 
mechanism of action by this protein. Firstly the functional domain in RFPL3 
that mediates the enhancement effect of PIC activity was investigated. RFPL3, 
ret finger protein-like 3, is a 288 amino acid protein with a molecular weight 
of approximately 32 kDa. In this study, a human isoform consisting of 867 
bases spreading over 4 identified family domains was used. A blast similarity 
search using the NCBI protein database revealed that the first N-terminal 
domain of RFPL3 contains a RING finger domain that is intrinsic to the 
function of a typical E3 ligase, allowing the latter to bind specifically towards 
E2 ubiquitin-conjugating enzymes to catalyze the proteasomal degradation 
pathway (Lorick et al., 1999). This domain stretches from amino acid 11 to 52. 
The second domain, the RFPL-defining motif (RDM), overlaps minimally 
with the first, stretching from amino acid 36 to 95, and is a conserved motif 
commonly found in all RFPL family proteins (Bonnefont et al., 2008). The 
third domain is a SPRY-associated domain (PRY) covering from amino acid 
98 to 146 and the forth domain is the SPRY domain from amino acid 148 to 
272. The PRY/SPRY combination domain has been identified in a number of 
proteins including several tripartite motif-containing proteins (TRIMs), as well 
as butyrophilin (Btns) and butyrophilin-like (Btnl) family members (Abeler-
Dorner et al., 2012; James et al., 2007). This domain is stipulated to be 
involved in a wide range of functions and has also been suggested to be a 
possible component of the innate immune defence (Grutter et al., 2006; Kawai 
and Akira, 2011).  
 In order to determine the RFPL3 domain required for the PIC 
activation, N’-terminal truncated domain mutants of RFPL3 as well as full-
length RFPL3 were generated from wheat germ cell-free system, following 
cloning methods described by ENDEXT® technology (Figure 3.5.1A). The 
full-length protein generated (GST-RFPL3 FL) contains all 288 amino acids of 
the RFPL3 protein covering all four domains. The first mutant (GST-RFPL3 
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Δ36) has a partially truncated RING domain, leaving only amino acid 36 to 52 
of the RING finger domain and the rest of the 3 domains intact. The second 
mutant (GST-RFPL3 Δ98) is truncated from the N’-terminal to amino acid 97, 
leaving the PRY/SPRY domain. The last mutant (GST-RFPL3 Δ148) is the 
shortest, containing only the last SPRY domain at the C’-terminal end (Figure 
3.5.1A).  
 All four proteins were expressed as N-terminal GST-fused proteins, 
affinity purified (Figure 3.5.1B), and subjected to the microtiter plate-based in 
vitro PIC assay using 10 nM of each recombinant protein. Figure 3.5.1C 
shows the effect of RFPL3 domain mutants on PIC activity, using wheat germ 
cell-free-produced GST-DHFR and the E. coli-produced proteins (GST-
RFPL3, GST-BAF and GST) as control proteins of the experiment. Similar to 
results in Section 3.4, E. coli-produced RFPL3 displayed significant 
enhancement of PIC activity when compared to GST control (14,868 ± 38.9% 
copies in GST-RFPL3 treatment and 2,792 ± 59.4% copies in GST-treatment, 
p< 0.01). This was likewise observed in GST-BAF positive control with 
quantified amount of integrated viral DNA to be 16,224 ± 28.1% copies (p< 
0.01 versus GST control). The wheat germ cell-free-derived full-length 
RFPL3 was also able to significantly enhance PIC activity by 14.3 times, 
when compared to the GST-DHFR control (18,065 ± 26.6% copies vs 1,260 ± 
17.0% copies; p< 0.01). With the partial removal of the RING domain, GST-
RFPL3Δ36 showed a substantial reduction in the ability to enhance PIC 
integration activity, being only able to enhance by 5.8 times that of GST-
DHFR control (7,302 ± 30.7% copies; p< 0.05 versus GST-DHFR control) in 
the same experimental run using the same batch of PIC. With the entire 
removal of the RING domain in the remaining two mutants, enhancement 
effect by RFPL3 was completely abrogated (GST-RFPL3Δ98: 1,781 ± 38.5% 
copies and GST-RFPL3Δ148: 2,401 ± 53.4 copies%; p> 0.1 versus GST-
DHFR control). Hence, it was concluded that the RING domain is the essential 












































Figure 3.5.1 Effect of RFPL3 domain mutants on in vitro PIC integration activity.  
(A) Illustration of the amino acid sequences in full-length RFPL3 (wild-type) and its N’-
terminal truncated mutants, RFPL3Δ36 (partially deleted in RING domain), RFPL3Δ98 
(containing PRY/SPRY domain) and RFPL3Δ148 (containing SPRY alone). (B) Purified 
proteins from cell-free production. Size of GST-tagged proteins, GST-RFPL3 FL: 58kDa; 
GST-RFPL3Δ36: 55 kDa; GST-RFPL3Δ98: 47 kDa; GST-RFPL3 Δ148: 42 kDa; GST-
DHFR: 44 kDa. (C) Microtiter plate-based PIC integration assay with wheat germ cell-free-
derived RFPL3 proteins and E .coli-produced control proteins. 10 nM of each protein was 
incubated with 25 μl of PIC respectively before addition to each well for in vitro integration 
assay. GST-DHFR was used as the negative control for cell-free derived proteins whereas 
GST protein was used as the control for E. coli derived proteins. E. coli derived proteins were 
included as positive controls to ensure a true and equivalent enhancement effect from cell-free 
derived full-length RFPL3 (wild-type). The experiment was done in triplicates with data 



































































3.5.2 DNA-binding ability of RFPL3 
 Following the identification of the functional domain causing PIC 
enhancement, the next step was to identify the binding target of RFPL3 within 
the PIC. However, since the PIC contains a multitude of viral and cellular 
proteins that have not been fully elucidated as yet, hence it may be difficult to 
pinpoint a specific protein target. On the other hand, it is easier to first 
determine if RFPL3 binds to viral DNA, by checking the DNA binding ability 
of RFPL3.  
The BAF protein has been reported to be an enhancer of PIC activity 
through preventing the auto-integration of viral DNA thereby ensuring the 
integrity of the latter for an efficient insertion during the integration process 
(Suzuki and Craigie, 2002). In vitro studies have also revealed that BAF is a 
DNA-binding protein that interacts with double-stranded DNA with no 
detectable sequence specificity (Zheng et al., 2000). Hence, following the 
example of BAF enhancing PIC activity through the binding and bridging of 
viral DNA, a gel-shift assay was performed with BAF and RFPL3, to test if 
the latter is also a DNA-binding protein and can therefore bind to viral DNA 
as part of its mechanism to associate with and enhance PIC activity.  
DNA substrate (691 bp) was generated from the digestion of pUC19 
and incubated with the respective proteins for 1 h at 30°C. The mixtures were 
then separated on an agarose gel via electrophoresis, and southern blot 
detection was performed to detect the substrate DNA. If the protein has DNA 
binding ability, it is expected to form a nucleoprotein complex with the DNA 
substrate during the incubation. This nucleoprotein complex is likely to 
migrate at a slower rate during gel electrophoresis, hence appearing as an 
additional upper band when the substrate DNA is detected using southern blot 
analysis.  
Figure 3.5.2 below shows the result of the gel-shift assay. Slower 
migrating band was observed in sample containing BAF, indicating the DNA 
binding activity of BAF. However, only a single substrate band was detected 
in reactions with GST-RFPL3 as well as control GST-DHFR, which coincides 
with that of substrate DNA only sample without protein. Hence, from the 
difference in the results between RFPL3 and BAF, it can be concluded that 
RFPL3 is not a DNA-binding protein unlike BAF, and probably enhances PIC 
59 
 
activity through a different mechanism, likely interacting with a protein 




Figure 3.5.2 Gel-shift assay to test the DNA-binding activity of RFPL3.  
Respective recombinant proteins (25 nM) were incubated with 250 pM of susbtrate DNA 
derived from pUC19 vector (691bp) for 1 h at 30°C. The mixtures were separated via gel 
electrophoresis on a 0.5% agarose gel and southern blotting analysis was carried out to detect 
substrate DNA using an AP-labelled substrate DNA probe. GST-BAF acted as the positive 












3.5.3 Effect of RFPL3 on integration activity of MoMLV PIC  
 The MoMLV is also a retrovirus belonging to the same retroviridae 
family as HIV-1 but of a different genus, the Gammaretrovirus. The MoMLV 
has been widely used as a model for the study of retroviral infections 
including PIC research due to the simplicity of the viral machinery involved, 
which encodes only Gag, Pol, and Env proteins that will be assembled into 
progeny virus particles. HIV-1, however, encodes 6 additional accessory 
proteins and belongs to a more complex retroviral model (Rein, 2011). 
Another stark difference lies in the fact that MoMLV replicate mainly in 
dividing cells, whereas HIV-1 is able to infect terminally differentiated cells 
such as the macrophages (Suzuki and Craigie, Nat Rev Microbiol, 2007). 
  In order to analyze the specificity of RFPL3 on promotion of retroviral 
PIC activities, the MoMLV PIC was subjected to the microtiter plate-based in 
vitro integration assay in place of HIV-1 PIC to test if RFPL3 can retain its 
enhancement effect on the activity of MoMLV PIC. This is important since if 
RFPL3 enhances both the MoMLV and HIV-1 PIC, it would possibly suggests 
that the mechanism of target by RFPL3 is an evolutionarily conserved viral 
protein present in all retroviruses, thereby guiding the elucidation of the role 
of RFPL3. On the other hand, if RFPL3 fails to enhance MoMLV PIC activity, 
then RFPL3 probably targets on a protein component unique to HIV-1 PIC. 
MoMLV PICs were isolated from NIH3T3 cells co-cultured with 
MoMLV-producing clone 4 cells. The isolated MoMLV PIC was first treated 
with E. coli-produced GST-RFPL3, before adding to the microtiter plate for 
the in vitro PIC integration assay.  BAF, which has been reported to enhance 
the activity of both HIV-1 and MoMLV PICs, was used as a positive control 
for the treatment. Figure 3.5.3 shows the results for the PIC assay. The amount 
of quantified viral DNA was expressed as a ratio that of the control GST 
treated PICs, which was set at 1.0. Essentially, GST-RFPL3 treatment gave a 
quantified ratio of 1.38 ± 0.5, which seems to suggest the absence of a 
significant enhancement of MoMLV PIC by RFPL3 (p-value= 0.4). In 
contrast, BAF treatment was able to increase the quantified ratio to 4.27 ± 2.4, 
showing substantial enhancement effect on MoMLV PIC (p-value= 0.08). The 
result was only substantial and not sufficiently statistically significant due to 
the wide variability in the data obtained. The activity of the isolated MoMLV 
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PIC was not as high as that for HIV-1 PIC, thus the detected viral copy 
number was low, contributing to a large SD upon calculation. Nonetheless the 
enhancement effect of BAF was still observed based on a higher amount of 
quantified integrated product when compared to negative control GST whilst 
that for GST-RFPL3 remains low.  
Following the results, it can therefore be concluded that RFPL3 
specifically enhances HIV-1 PIC activity, but not the MoMLV PIC. This 
indicates that the target of action is probably a protein component specifically 





Figure 3.5.3 Microtiter plate-based in vitro PIC assay with RFPL3 using MoMLV PIC. 
MoMLV PICs were isolated from the co-culture of NIH3T3 cells and MoMLV-producing 
clone 4 cells and subjected to treatment with E. coli-derived GST-RFPL3, BAF and GST 
control proteins before adding to the PIC integration assay. Results were displayed as relative 
ratio of quantified viral DNA copies to that of quantified DNA for GST control (mean set at 




3.5.4 Interaction of RFPL3 with HIV-1 IN 
 The key players of HIV-1 integration process are none other than the 
viral DNA as well as essential IN protein which catalyses the insertion 
reaction. RFPL3 was shown to enhance PIC activity, but it was previously 
shown that RFPL3 is not a DNA-binding protein and therefore is instead likely 
to interact with a protein component of the PIC to modulate integration 
efficiency. Since HIV-1 IN is a critcal component of the PIC and an 
indispensable viral protein for the integration reaction, direct interaction 
between recombinant HIV-1 IN and RFPL3 was tested in vitro.  
 The AlphaScreen assay (Perkin Elmer) is a luminescence-based 
binding assay, which allows biomolecular interactions and activities to be 
determined and monitored in vitro (Demeulemeester et al., 2012). The system 
relies on the use of donor and acceptor beads that can bio-conjugate with 
specific recognition tags attached to the binding proteins to detect any protein-
protein interaction. In this experiment, protein interaction was monitored using 
His-tagged recombinant HIV-1 IN and GST-tagged RFPL3 through the 
AlphaScreen assay (Figure 3.5.4A). Glutathione donor beads and nickel 
chelate acceptor beads were used, which will recognize GST-tag on RFPL3 
and His-tag on IN, respectively. If the proteins interact and bind, the donor and 
acceptor beads will be brought into close proximity. Upon illumination at an 
absorbance wavelength of 680 nm, excitation of the donor bead bound to one 
protein partner will generate singlet oxygen (1O2), and its chemical energy 
causes the diffusion of singlet oxygen to nearby acceptor bead conjugated to 
the other protein interacting partner. Subsequently, this results in the emission 
of a chemiluminescent signal by the acceptor bead, detected at a wavelength 
of 520-620 nm (Ullman et al., 1994).  
 The LEDGF protein is a well-known interactor of HIV-1 IN and has 
been widely used in AlphaScreening assays in the search for small compounds 
that can inhibit the LEDGF-IN interaction to complement the current anti-HIV 
therapy (Hou et al., 2008). In this experiment, GST-LEDGF was included as a 
positive control for the assay. Negative controls included GST-DHFR and 
His-DHFR. Figure 3.5.4B shows the His-IN and GST-LEDGF and His-DHFR 
used in AlphaScreen assay.  
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 GST-RFPL3 was incubated with His-IN for 1 h in a binding reaction 
before the addition of glutathione donor and nickel acceptor beads. The 
mixture was incubated in the dark for 1 h, after which the fluorescence was 
measured. GST-LEDGF (positive control) and GST-DHFR (negative control) 
were also incubated with His-IN. In order to account for the stickiness of 
GST-proteins in the reaction, a negative control protein, His-DHFR, was 
incubated with the three GST-tagged proteins instead of His-IN. Figure 3.5.4C 
shows the results of the AlphaScreen assay. The mean fluorescence level for 
GST-tagged protein/His-IN reaction was expressed as a ratio that for reactions 
containing His-DHFR and respective GST-tagged proteins, taking the mean 
relative value for GST-DHFR control as 1.0. GST-RFPL3 has a mean relative 
ratio of fluorescence at 1.20 ± 0.74, which is not statistically different from 
that of GST-DHFR (p-value = 0.13). This is in contrast to the mean relative 
ratio of fluorescence for GST-LEDGF at 6.42 ± 4.55 (p-value < 0.05), 
showing a clear interaction between GST-LEDGF and His-IN. Hence, it can 
be concluded that since in vitro interaction between His-IN and GST-RFPL3 
is minimal, HIV-1 IN is dispensable to the enhancement effect of RFPL3 on 








Figure 3.5.4 AlphaScreen assay to check the in vitro interaction between RFPL3 and 
HIV-1 IN. (A) Illustration of the AlphaScreen reaction. GSH donor beads recognize and bind 
to GST-tag on RFPL3 whereas nickel chelate acceptor beads bind to His-tag present on IN 
protein. When proteins interact, the donor and acceptor beads are brought into close 
proximity, causing the release of a singlet oxygen atom upon excitation and the emission of 
fluorescence signal. (B) CBB analysis on the purified control proteins. Size of protein, His-IN: 
32 kDa, His-DHFR: 26 kDa and GST-LEDGF: 44 kDa. CBB of GST-RFPL3 and GST-DHFR 
was previously shown in Figure 3.5.1B. (C) AlphaScreen results for GST-RFPL3 and His-IN 
interaction. The relative mean fluorescence measured from GST-protein and His-IN 
interaction was expressed as a ratio that of interaction between GST-protein and His-DHFR 
control. The mean fluorescence ratio for GST-DHFR control protein was set at 1.0. The 




3.6 Cell-based validation studies  
3.6.1 Cellular localization of candidate E3 ligases 
 Since functional PIC is thought to be formed in the cytoplasm of 
infected cells after reverse transcription of the viral genome (Bushman and 
Craigie, 1991), cellular modulators therefore need to associate with PIC in 
cytoplasm. Hence, cellular localization of candidate proteins was investigated 
by immunofluorescence assay (IFA) using human cell lines stably expressing 
FLAG-tagged E3 ligases. Third generation lentiviral vectors carrying a FLAG-
tagged candidate gene and blasticidin resistant gene were produced as VSV-G-
pseudotyped virus, and 293T cells were transduced with the infectious 
lentiviral vectors. The stable cell lines were established by selecting in 
blasticidin-containing medium over one week, and then collected to check the 




Figure 3.6.1-1 Immunoblotting analysis to check the expression of candidate proteins in 
293T cells. Stable cell lines stably expressing a FLAG-tagged candidate protein was 
established by lentiviral vector transduction and blasticidin selection. Cells were lysed in 
RIPA buffer and and resolved on a 12%SDS-PAGE gel. Immunoblotting was performed using 
HRP-conjugated anti-FLAG antibody. Size of FLAG-tagged proteins, RFPL3: 38 kDa; 





To carry out IFA, stable cell lines were seeded in 8-well chamber slide 
and fixed with PFA followed by treatment with anti-FLAG primary antibody 
and Alexa Fluor 488-conjugated secondary antibody. Cells were also 
counterstained with DAPI (blue) for the identification of nuclei. Figure 3.6.1-2 
shows the IFA results for 293T cells expressing FLAG-tagged RFPL3 (A), 
RNF25 (B), STUB1 (C), TRIM52 (D), and control DHFR (E). Most of the 
FLAG-RFPL3 (green, panel A) was observed to localize mainly in the 
cytoplasm, suggesting the possibility that RFPL3 is able to associate with 
PICs in HIV-1-infected cells. Among the other candidate proteins, FLAG-
RNF25 and FLAG-STUB1 were also localized mainly to the cytoplasm, 


























Figure 3.6.1-2 Localization of candidate proteins in 293T cells. Stable cell-lines were each 
seeded in chamber slides and fixed with 4% PFA. Staining of candidate proteins was done 
using anti-FLAG rabbit antibody followed by secondary antibody Alexa 568-conjugated anti-
rabbit IgG (Green). Cell nuclei were stained with DAPI (Blue). Slides were observed under a 
40X Olympus IX81 fluorescence microscope. RFPL3 (A) was found to localize throughout 
the cytoplasm. RNF25 (B) and STUB1 (C) also localized throughout the cytoplasm, while 
TRIM52 (D) localized mainly in cell nuclei.  (E) Control DHFR-expressing stable cells; (F) 






3.6.2 Association of RFPL3 with HIV-1 PIC in infected cells  
 The cytoplasmic localization of RFPL3 in stable 293T cells (Section 
3.6.1) gave an indication of its ability to associate with PIC upon its formation 
in the same locality. In order to examine an interaction of RFPL3 with HIV-1 
PIC in virus-infected cells, co-immunoprecipitation analysis of the HIV-1 PIC 
from FLAG-tagged RFPL3-expressing cells was carried out.  
293T cells expressing FLAG-RFPL3 was infected with HIV-1 vectors, 
and the PICs were isolated at 7 h after infection. PICs from FLAG-DHFR-
expressing cells were also used as the control for the experiment. The PICs 
were briefly purified through a gel-filtration spin column and incubated with 
anti-FLAG antibody followed by protein A/G agarose beads. Upon 
centrifugation, the protein complexes were pulled down along with the beads.  
The co-immunoprecipitated samples were then subjected to proteinase K/SDS 
treatment to deproteinize the PICs present, followed by phenol-chloroform 
extraction for DNA isolation. Since viral DNA is a component of the PIC, the 
presence of viral DNA in precipitates indicates that PIC is being co-
immunoprecipitated along with the FLAG-tagged protein by anti-FLAG 
antibody, suggesting direct interaction of the protein with PIC in infected 
cells. The purified viral DNA samples were then subjected to PCR 
amplification, before being visualized on a 1.5% agarose gel by 
electrophoresis. HIV-1 R-U5 primers AA55 and M667 that specifically detect 
the LTR region of early viral reverse transcripts were used to detect the viral 
DNA extracted from the immunoprecipitated PICs.  
Figure 3.6.2 shows the PCR products after 28 cycles of amplification, 
followed by gel electrophoresis on a 1.5 % agarose gel stained with ethidium 
bromide. Viral DNA was detected only in the PIC sample derived from 293T 
cells expressing FLAG-RFPL3, but not control FLAG-DHFR. This indicates 
that RFPL3 associates with PIC in the cytoplasm of the infected cells. No viral 
DNA was detected from the FLAG-DHFR control even after PCR 
amplification, while input fractions act as an indication of same levels of viral 





Figure 3.6.2 Co-immunoprecipitation analysis of HIV-1 PICs derived from RFPL3-
expressing 293T cell line. Cells were infected with lentiviral vectors and the cellular 
cytoplsmic fraction containing PICs were isolated. PIC samples were gel-filtrated and 
incubated with ant-FLAG antibody (Ab) followed by A/G agarose beads. Upon 
immunoprecipitation, PICs were inactivated by proteinase K/SDS treatment and viral DNA 
was extracted via phenol-chloroform method. An additional PCR was performed to amplify 
the amount of viral DNA extracted using specific HIV-1 R-U5 primers, before the latter is 
visualized on a 1.5% agarose gel through ethidium bromide staining after gel electrophoresis. 
Input fractions give an indication of the amount of viral DNA present in each initial sample of 
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3.6.3 HIV-Luciferase assay on infected RFPL3-expressing 293T cells  
 Upon confirming the cellular association of RFPL3 with HIV-derived 
PIC in RFPL3-expressing 293T cells, we went on to check the effect of 
increased RFPL3 expression on the infectivity of the cells.  For the purpose of 
this study, the pYK005c lentiviral vector expressing the luciferase (Luc) 
reporter gene was used to produce HIV-derived viral supernatant for infection. 
The p24CA level of the virus was quantified and 10 ng p24CA virus was added 
to 1×105 of RPL3 or DHFR-expressing stable cells. Infection was performed 
for 48 h, after which cells were lysed and the amount of luciferase expression 
was quantified, based on the level of luminescence detected. Luciferase 
activity derived from the HIV-Luc assay is an indication of the level of 
infectivity to the cells, in terms of the viral genome transcription, and thus the 
successful integration of the HIV-Luc DNA genome into host chromosome.  
Hence, it allows us to assess and validate the cellular effect of RFPL3 on PIC 
integration activity in 293T cells.  
 From figure 3.6.3, the mean relative light units (RLU) detected from 
luciferase activity of RFPL3-expressing cells infected with HIV-Luc was 
378,043.5 ± 18.9%, higher than that of the mean RLU from DHFR-expressing 
control cells (258,639.9 ± 5.9%; p< 0.05). This indicates that infectivity in 
RFPL3-expressing cells was higher, probably suggesting an enhancement 
effect by RFPL3 on the integration of viral genome and therefore its 
transcription along with the luciferase reporter gene in infected cells. Hence, 
in this experiment, we successfully demonstrated the enhancement effect of 
RFPL3 on HIV-1 replication, supporting the hypothesis that RFPL3 is a true 













Figure 3.6.3 HIV-1 luciferase assay on RFPL3-expressing 293T cell line.  
1×105 cells were infected with 10 ng p24 lentiviral vector pYK005c carrying luciferase 
reporter gene. Cells were lysed 48 h post infection and the amount of luciferase activity in 20 
μl of cell lysate was quantified. Protein concentration was measured using Bradford assay for 
the normalization of luciferase activity across all samples. The experiment was done in 















































CHAPTER 4: DISCUSSION 
4.1 The importance of the study 
4.1.1 Clinical significance: Developing treatment strategies targeting the 
HIV-1 integration process with minimized resistance development 
Early phase of retroviral replication consists of two characteristic 
processes: reverse transcription to produce the viral cDNA and integration of 
the viral genome within the host chromosome. This insertion of the viral 
genome to produce a provirus is especially important for the virus to establish 
a permanent infection for the production of its viral progenies at the expense 
of host machineries. Hence, integration can be considered a key step that 
determines the infectivity of the retrovirus particle.  
In the development of antiretroviral drugs (ARVs), focus has been on 
identifying distinct steps and inhibiting the critical viral proteins involved. 
Inhibitors that target the reverse transcription step to abrogate the production 
of cDNA from the viral RNA are the most well studied, occupying 13 out of 
the 24 FDA-approved ARVs. However, the integration step has been the least 
well targeted, and currently, only two IN strand transfer inhibitors (InSTIs), 
raltegravir, and elvitegravir, are approved ARVs (Arts and Hazuda, 2012). 
This means that the area of integration has not been fully exploited for target 
inhibition and there is definitely potential for the development of more 
effective drugs abrogating integration.  
As the search for more effective antiretroviral drugs continues, one of 
the biggest challenges in the treatment of HIV infection is nonetheless the 
development of resistance against the ARVs due to the fact that most drugs 
target the active sites of viral enzymes with a high rate of mutation (Busschots 
et	 al., 2009). This is especially so for the InSTIs, raltegravir and elvitegravir. 
Due to the highly selective effect of strand transfer, these inhibitors have 
similar components with well-defined mechanism of action, (i) a metal-
binding pharmacophore that sequesters magnesium cofactor ions and (ii) a 
hydrophobic group that interacts with the viral DNA as well as IN protein. In 
fact, clinical trials with raltegravir have revealed that resistant mutants which 
developed eventually became cross-resistant to both first and second 
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generation strand transfer inhibitors, challenging the effectiveness of 
subsequent treatments with drugs of the same class (DeJesus et	al., 2007).  
In light of these issues, new efforts to abrogate the integration process 
have turned towards developing inhibitors against drug-resistant viruses and 
obligate IN cofactors. Assays to monitor the protein-protein interactions with 
purified IN have been established, including AlphaScreen assays and in silico 
fragment-based screening (Christ et al., 2010; Hou et al., 2008), which gave 
rise to the discovery of non-catalytic site IN inhibitors BI 224436 and 
LEDGINs— a group of small molecules designed to potently inhibit the IN-
LEDGF interaction, instead of the IN active site with an innately high 
mutation rate (Karmon and Markowitz, 2013). The molecules allosterically 
bind to the CCD–CCD pocket on IN, originally occupied by LEDGF cofactor 
in order to bring the viral protein in closer proximity with the host 
chromosome for integration (Engelman et al., 2013). BI 224436 was able to 
demonstrate in vitro effectiveness against HIV-1 infection, and has since 
progressed into phase I of clinical trials, whereas LEDGINs were still in the 
making, requiring further development before proceeding to clinical testing 
(Karmon and Markowitz, 2013).  
Following the success of identifying compounds targeting the non-
catalytic IN-LEDGF interaction, additional efforts are now focused on other 
possible IN-cofactor targets and host factors that affect integration efficiency 
with minimized chances of resistance development. The main objective of our 
study is therefore to identify a novel cellular factor that can modulate in vitro 
integration activity by using a rapid screening system that allow us to monitor 
integration efficiency upon the addition of exogenous cellular factors in real-
time. Consequently, our study greatly contributes to the understanding of the 
integration system in its full cellular context, which is important in fulfilling 
the clinical significance of revealing a novel target mechanism for the 
development of a new generation of treatment that will retain potency even 




4.1.2 Scientific significance: Advancing knowledge on the aspects of 
retroviral integration through the revelation of PIC modulators and its 
components 
In order to study integration in vitro, researchers have engaged the use 
of purified recombinant IN protein. However, it was demonstrated that during 
the in vitro study of integration activity, purified recombinant IN protein often 
fail to produce an authentic and complete integration. A highly possible reason 
lies in the fact that cellular viral integration requires the orchestration of a 
nucleoprotein complex termed the PIC, consisting of the IN, viral DNA and 
many other viral and host proteins that ensure the stability and integrity of the 
previous two core players of the integration reaction. Studies have also shown 
that small chemical compound inhibitors identified from IN assays were 
eventually unable to retain full in vitro effectiveness against integration when 
employed in assays using isolated PICs from HIV-1 infected cells, with most 
of them exhibiting a dramatic increase in their IC50 (Farnet et al., 1996). This 
indicates that the PIC-based assay is more selective and should be employed in 
in vitro assays to replicate a test-tube environment closest to that of in vivo 
physiological conditions for the study of integration and the involvement of 
cofactors.  
In order to proceed further in the development of non-catalytic 
inhibitors of the integration process, there is an impetus need to understand the 
PIC components and hence retroviral integration in more detail. However, it 
has been an arduous task to unveil the cellular components of the HIV-1 PIC. 
To date, only a handful of cellular factors have been identified as the 
components and modulators of the PIC through reconstitution analysis as well 
as immunoprecipitation assays. Moreover, conventional assays using retroviral 
PICs are often laborious involving time-consuming southern blotting assays 
and the use of radioisotopes, lacking the simplicity required of high-
throughput screening studies on integration activity (Hansen et al., 1999). As a 
result, large-scale protein screening for new cellular factors affecting PIC 
activity has not been performed and is a novel aspect of this project.  
Consequently, the revelation of new PIC-interacting host partners and 
the elucidation of their functional roles can indeed allow us to gain deeper 
insights into the complex molecular crosstalk between retrovirus and cellular 
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cofactors and to better understand the molecular aspects of retroviral 
integration. Coupled with a rapid system as such, it will also hasten the 
investigation and development of a new generation of antivirals targeting the 
critical integration process of HIV-1 infection with lower chances of viral 





















4.2 Establishment of novel microtiter plate-based PIC integration assay in 
combination with wheat germ cell-free protein production system for the 
screening of host modulators 
4.2.1 The wheat germ cell-free protein production system 
 The microtiter plate-based screening of PIC modulators would not 
have been possible without employing the wheat germ cell-free protein 
synthesis technology that allows for a high-throughput production of good 
quality proteins for screening. The wheat germ cell-free system made use of 
extensively washed wheat embryos devoid of contamination by endosperm 
and other source of ribosome inhibitors to carry out high speed and accurate 
cell-free protein synthesis, thereby providing a very stable translational 
apparatus for the preparation of large amounts of active protein from a 
eukaryotic source (Madin et al., 2000). As a result, protein production can be 
performed in a 96 well-plate format with low amount of starting materials 
required, allowing a one-time production of up to 384 proteins when using an 
automated GenDecoder 1000 protein synthesizer (CellFree Sciences). Coupled 
with the Gateway vector system, this technology has allowed the successful 
expression of 13,364 human proteins from gateway entry clones-derived 
mRNA, with 77% of the phosphatases tested showing biological activity in 
vitro. Also, of 96 randomly chosen ORF, two-thirds of the proteins 
synthesized were soluble (Goshima et al., 2008), indicating good structural 
conformation for further studies. In our study, we applied the Gateway 
technology to conveniently generate a human E3 ubiquitin ligase library 
containing 200 Gateway entry clones, out of which eventually 135 of them 
(~70%) were successfully produced through wheat germ cell-free system.  
In summary, advantages of using the wheat germ cell-free system 
include reduced cost due to low amount of starting materials required, ease of 
handling for high-throughput production, high expression efficiency with 
sufficient yield as well as the fact that proteins are produced from a eukaryotic 
source thus good quality of soluble human protein products can be obtained 
(Imataka and Mikami, 2009). However, it should be noted that one limitation 
of the system is their inability to produce human proteins complete with post-
translational modifications (PTM). In fact, cell-free system from wheat germ 
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extract is not capable of protein glycosylation (Mikami et al., 2006). As such, 
it could limit screening efficiency by masking the functional effect of proteins 
requiring certain types of PTMs including glycosylation. Nonetheless, the 
method allows for rapid production of a large number of soluble proteins, 
making it an ideal system for the preparation of protein libraries to be applied 
to a novel screen for PIC modulators using the microtiter plate-based 
integration assay.  
4.2.2 Evaluation on the effectiveness of the microtiter plate-based PIC 
integration assay for proteins 
 The development of a PIC integration assay using DNA-coated 
microtiter plates was first described in a study to screen a library of chemicals 
that are related to known IN inhibitors (Hansen et al., 1999). For the purpose 
of our study, we have adapted the PIC integration assay for a novel screen 
with proteins prepared from the wheat germ cell-free system to identify 
potential PIC modulators.  
Specificity of the assay was first checked using freshly isolated active 
PICs alone and proteinase K/SDS-treated inactivated PICs as control. The 
amount of viral DNA detected from the reaction incubated with active PIC 
was about 34 times that of the background DNA present in an inactivated PIC 
sample well (Figure 3.1.2), showing a statistically significant difference in 
integration activity that can be quantified from an active PIC sample using the 
assay platform. Subsequently, sensitivity test was carried out using known 
cellular enhancer and inhibitor of PIC activity, BAF and VRK, respectively. 
Increase in concentration of the BAF added could be translated into a higher 
amount of integrated DNA product quantified from the assay, indicative of an 
enhancement of PIC activity in a concentration-dependent manner (Figure 
3.1.4). An opposite effect was similarly observed in the test carried out with 
VRK, thereby demonstrating the sensitivity of the assay to detect even the 
strength of enhancement or inhibition of PIC activity by protein modulator 
added, relative to a positive control. 
Lastly, the reproducibility and suitability of the assay for high-
throughput screening was determined. A good platform suitable for high-
throughput screening often needs to show stability and reproducibility with 
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repeated test. There should also be a well-defined window between active data 
and the background noise. These conditions make up the Z-factor, which 
measures the gap between the standard deviation for the positive (active PIC) 
and negative (inactivated PIC) controls (Zhang et al., 1999). A good gap 
between the two and a narrow range of standard deviation will contribute to 
the power of the assay, and suitability for high-throughput screening with 
lower chances of having false-positives or missing out on false-negatives. An 
excellent assay produces a Z-factor ranging from 0.5 to 1 (Zhang et al., 1999).  
Being a nucleoprotein complex consisting of many cellular proteins as 
well as viral proteins, the components of the isolated PIC is extremely 
vulnerable to degradation, contributing greatly to the batch-to-batch variability 
of its content and functional efficiency. The nature of its variability can be 
observed from a wide window of quantified integrated products from the 
positive data points (10000 copies < mean ± 3xSD < 20000 copies), upon 
calculation of the Z-factor for the assay (Figure 3.1.5). A possible way to 
minimize the variation is to normalize the copy number of the viral DNA 
among the different batch of PICs used before quantifying the integrated 
products. However, even so, variability in the overall integration activity 
resulting from different culture condition of PIC-producing cells will still be 
observed. Fortunately, in the calculation of Z-factor, this was compensated 
with a fairly broad dynamic range between the positive data points (active 
PICs) and that of the negative controls (inactive PICs). The Z-factor was 
eventually calculated to be 0.56 (Figure 3.1.5), indicating that the PIC assay is 
a sufficiently robust and reliable platform with a well-defined hit window for 
the screening of novel PIC modulators.   
4.2.3 Restrictions on the screening process and selection of candidates 
 Two batches of preliminary screening were separately carried out with 
135 E3 ubiquitin ligases produced by the wheat germ cell-free system.  Even 
though the assay was tested to be sensitive and robust, the stability and 
reproducibility of the assay was often restricted by the batch-to-batch 
variability in content of the isolated PIC, which affects the level of functional 
integration activity that is quantified from the assay. In order to account for 
this difference, freshly isolated HIV-1 PICs were employed for every new 
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round of screening. This ensures minimal variability amongst the PIC added to 
each well of the microtiter plate assay within a particular screen per se, so as 
to more accurately compare the quantified strength of modulation relative to 
the negative control based on the amount of integrated product measured. 
However, this also means that the inter-variability between each round of 
screening is usually large and unaccounted for, since different batches of PICs 
with varied levels of activity were used. Thus, data from various rounds of 
screening should not be compared based on absolute value per se, but the 
relative fold change in effect, selecting candidates based on the consistency in 
its modulation effect across all rounds of screening.  
 Another limitation of the screening assay lies in the fact that the 
concentration of each E3 ubiquitin ligase added was not standardized. This is 
due to the hassle of having to measure the concentration of a large number of 
proteins and the limited amount of each eluted product available after 
purification. Hence, proteins with a true PIC modulation effect but poor 
expression from the wheat germ cell-free production may go undetected from 
the screen, having their effects masked by its low yield.  Attempts to control 
for such false negatives were taken into account by checking the availability 
and expression of the proteins through CBB and immunoblotting analyses and 
by excluding those with poor availability and expression from the subsequent 
PIC integration assay. Also, in order to ensure that protein expression is not 
compromised by experimental restrictions in the transcription and translation 
processes, different batch of E3 ubiquitin ligases were produced at least twice 
from the wheat germ cell-free system so as to demonstrate the consistency of 
the modulation effect of each protein on PIC integration assay. Nonetheless, 
the strength of the modulation effect exhibited by each remaining protein may 
still be affected by its level of expression and availability, contributing to a 
restriction of the assay that is unaccounted for. The only reasonable way to 
rectify the problem is therefore to perform multiple rounds of screening and 
selecting candidates based strictly on a consistently reproducible effect that 
must also be significant in all rounds of tests.  
Candidate proteins were then selected for large-scale production using 
the bacterial E. coli system, the only alternative method available in our 
laboratory for protein production. A possible shortcoming of the E. coli 
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system however lies in the absence of post-translational modifications that 
may be necessary for the production of fully functional mammalian proteins, 
which might influence the true activity of the candidate proteins on the PIC 
function. Nonetheless, the E. coli system allows for the production of large 
amount of the candidate proteins, facilitating a concentration-dependent study 
and validation of their modulating effect on HIV-1 PIC in Section 3.4, based 
on a different source of protein production other than the wheat germ cell-free 
system.  
 On the other hand, the HIV-1 PIC consists of the viral DNA, viral 
proteins as well as a complex of host proteins that are essential to the 
mediation of the integration process. Thus, it is possible that the complex may 
already contain in minute amount the endogenous form of the E3 ubiquitin 
ligase that is necessary for integration. When more of the protein was added 
exogenously, the enhancement effect may be too modest to be observed. As a 
result, the true effect of the protein could have been masked during the PIC 
integration assay, contributing to the possibility of false negative data.  
Additionally, it may also be harder to identify candidate inhibitors 
from the integration assay using isolated PICs. This is largely due to fact that 
most of the essential components for integration are already present in the 
PIC, therefore a single exogenously added factor may not be able to fully 
perturb the stability or even sufficiently inhibit its functional activity during 
the integration assay. The lower capability of the assay to capture candidate 
inhibitors can be observed from the validation study using various 
concentrations of the selected inhibitors RNF25, STUB1 and TRIM52 in 
Section 3.4. In fact, at a concentration of 1 nM, all of the inhibitors, including 
the known inhibitor VRK could not show a decrease in PIC activity to below 
that of the GST negative control. The candidate enhancer RFPL3 and the 
enhancer control BAF, were however able to exert at least 30% increase in 
PIC activity when added at 1 nM each. Positive control for inhibitors, VRK, 
was only able to exert an effect on PIC activity when added at 10 nM, 
inhibiting the amount of integrated product formed by 30%. None of the 
candidates were able to show a statistically significant decrease in PIC activity 
even at 10 nM, indicating that a higher concentration is probably required to 
reproduce the inhibition effect, or perhaps they are simply false positive 
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candidates of the preliminary screening. This demonstrated the difficulty of 
the microtiter plate-based PIC assay to screen out potential inhibitors as 
compared to enhancers, especially when PICs comprising most of the essential 
factors needed for integration, were used. Taking all pointers into 
consideration, it is thus necessary to repeat the in vitro screen for multiple 
times and to perform validation studies using various protein concentrations 
before a candidate protein, showing consistently significant modulation effect 
that is also concentration dependent, can be confirmed as a true enhancer or 
inhibitor of the in vitro PIC assay, as in the case for RFPL3.   
4.3 Introduction to candidate proteins 
 Based on the multiple rounds of preliminary screening, a total of 8 
candidate proteins have been selected, of which 3 were potential enhancers 
(RFPL3, TRAF5 and TRIM61) whilst 5 were potential inhibitors (RNF25, 
STUB1, TRIM52, RSPRY1 and MYLIP) of the HIV-1 PIC.  
4.3.1 Potential HIV-1 PIC enhancers  
RFPL3 
 The ret finger protein-like 3 (RFPL3) protein is part of the RFPL 
protein family which shares a 58% similarity in its genetic sequences with the 
ret finger proteins (RFP), and hence its name (Seroussi et al., 1999).  RFP 
belongs to the large B-box RING finger protein family which are nuclear 
proteins that may function in growth regulation, or become oncogenic by 
fusion with RET tyrosine kinase (Cao et al., 1998; Shimono et al., 2000). RFP 
and RFPL share similarity mainly in the RING-like motif and the B30-2 
domain bridged by a coiled–coil domain, which were domains believed to be 
important in mediating protein–protein interactions by promoting homo- or 
heterodimerization (Seroussi et al., 1999). The RING domain is also the 
functional domain of RFPL3 as an E3 ubiqutin ligase, which exhibits binding 
activity towards E2 ubiquitin-conjugating enzymes to mark proteins for 
proteasomal degradation. Other domains found in RFPL3 include the RFPL 
defining motif, which is a conserved domain on RFPL proteins, the PRY 
domain of unknown function, and a SPRY domain that has been identified in 
at least 11 protein families (NCBI, 2013). The PRY domain was found in 
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butyrophilins, butyrophilins-like proteins and TRIM proteins implicated in cell 
growth, development and human immune responses. The SPRY domain has 
been found in proteins involved in a wide range of functions including 
regulation of cytokine signalling (SOCS), RNA metabolism (DDX1 and 
hnRNP), immunity to retroviruses (TRIM5α), intracellular calcium release 
(ryanodine receptors or RyR) and regulatory and developmental processes 
(HERC1 and Ash2L). The RFPL3 protein is differentially expressed in human, 
with higher levels commonly found in the brain, bone marrow and prostate 
gland (Expression-Atlas, 2013). Other than the role of RFPL 1, 2 and 3 in 
neocortex development (Bonnefont et al., 2008), functions of the RFPL3 per 
se has not been well reported and remains largely unknown.  
 
TRAF5 
 The TNF receptor-associated factor 5 (TRAF5) is a member of the 
tumor necrosis factor receptor-associated factor (TRAF) protein family, 
containing a meprin and TRAF homology (MATH) domain comprising of 
metalloproteases that are capable of cleaving biologically active peptides, a 
RING finger domain, and two TRAF-type zinc fingers. TRAF proteins 
associate with members of the tumour necrosis factor (TNF) receptor 
superfamily to mediate TNF-induced activation and phosphorylation of 
inflammatory factor NF-kB, resulting in the activation of transcription factors 
and the regulation of cell survival, proliferation and stress responses in the 
immune and inflammatory systems (Sakurai et al., 2003). More importantly, 
TRAF5 has been reported to be a crucial molecule in mediating the production 
of type I interferons and the activation of innate immune responses activation 
against viral infection (Tang and Wang, 2010). Additionally, significant up-
regulation of TRAF5 gene expression was found to be essential in triggering 
HIV-1 gp120-induced neuronal apoptosis when potentiated by ethanol in the 
early stages of interaction (Chen et al., 2005b).  
 
TRIM61 
 The tripartite motif containing 61 (TRIM61) protein is a member of the 
TRIM family proteins that commonly comprises of both the RING finger 
domain and the B-box-type zinc finger, a zinc-binding domain that mediates 
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protein-protein interaction. TRIM family proteins are found to be involved in a 
wide range of functions including cell proliferation, differentiation, 
development, oncogenesis and apoptosis. More recently, there has been 
increasing evidence of TRIMs, especially TRIM19 and TRIM5α, playing a 
role in retroviral restriction and antiviral defence, representing a new and 
widespread class of antiviral proteins involved in innate immunity (Nisole et 
al., 2005). The role of TRIM61 is however largely unknown, although there 
have been reports of its genetic association with the pathophysiology of 
childhood obesity in the Hispanic population (Comuzzie et al., 2012).  
4.3.2 Potential HIV-1 PIC inhibitors  
RNF25 
  The ring finger protein 25 (RNF25) protein contains 2 conserved 
domains namely the RING finger as well as a RWD domain, a region 
containing WD repeats within the RING finger that is related to the ubiquitin-
conjugating enzyme E2, catalytic domain. The mouse counterpart of this 
protein has been shown to interact with the p65 subunit of NF-kB thereby 
supporting NF-kB-mediated transcription activity (Asamitsu et al., 2003). 
RNF25 is also more commonly reported to be involved in E2-dependent 
ubiquitinylation and proteasomal degradation of proteins (Lorick et al., 1999).  
 
STUB1 
 The STIP1 homology and U-box containing protein 1 (STUB1) has 
been reported to be an E3 ubiquitin ligase that participates in protein quality 
control by targeting chaperone protein substrates for degradation (Min et al., 
2008). The protein has 3 conserved domains namely the tetratricopeptide 
repeat (TPR) domain, commonly found in chaperones, cell-cycle proteins, 
transcription factors and protein transport complexes; a TPR repeat and a U 
box domain related to the RING finger but lacking zinc binding residues. 
STUB1 has been reported to be an upstream regulator of oncogenic pathways 
(Kajiro et al., 2009), potentially acting as a tumour suppressor by regulating 
the stability of c-Myc (Paul et al., 2013), and a decrease in its expression was 
also found to correlate with lymph node metastasis in gastric cancer (Gan et 
al., 2012). STUB1 is also a regulator of the expression of other proteins 
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including histone deacetylase 6, PTEN and CARMA1 (Ahmed et al., 2012; 
Cook et al., 2012; Wang et al., 2013). More importantly, STUB1 has been 
shown to physically interact with HIV-1 Vif protein in 293T cells through 
affinity purification and mass spectrometry analyses (Jager et al., 2012).  
 
TRIM52 
 The tripartite motif containing 52 (TRIM52) protein is another member 
of the TRIM family protein. The exact role and function of the TRIM52 E3 
ubiquitin ligase in cells is however not reported.  
 
MYLIP 
 The cytoskeletal effector (ERM) proteins including ezrin, radixin and 
moesin, are proteins that link actin to membrane-bound proteins at the cell 
surface and are involved in signal transduction pathways. The myosin 
regulatory light chain interacting protein (MYLIP) is a novel ERM-like 
protein that interacts with myosin regulatory light chain and regulates cell 
motility by inhibiting neurite outgrowth (Olsson et al., 1999). The neurite 
outgrowth inhibitory activity of MYLIP was attributed to its RING domain. 
The protein also contains a FERM domain, which is characteristic of ERM 
proteins. MYLIP was found to be responsible for the ubiquitination and 
degradation of low-density-lipoprotein (LDL) receptor, which reveals novel 
insights into the study of LDL receptor levels and cholesterol metabolism in 
various diseases (Lindholm et al., 2009).  
 
RSPRY1 
The RSPRY1 protein contains a RING finger and SPRY domain, 
hence the derived name of the protein.  These two domains were also present 
in the potential HIV-1 PIC enhancer candidate RFPL3. However, no studies or 




4.4 Mechanism of RFPL3 in mediating enhancement of PIC activity 
4.4.1 Comparing the conserved domains of RFPL3 with that of a protein 
of known effect on HIV-1 to elucidate a possible mechanism of action  
 As mentioned previously, little is known about the function and 
cellular roles of the RFPL3 protein. Hence, information about the protein can 
only be extrapolated based on the conserved domains within RFPL3. For 
instance, the RING domain of RFPL3 gives it a characteristic feature that of 
an E3 ubiquitin ligase, with the ability to interact with E2 conjugating enzyme 
to mark proteins for proteasomal degradation. Additionally, RFPL3 also 
contains the PRY/SPRY domain, which has been found in a wide range of 
proteins reported to perform functions including cell growth and regulating the 
human immune system. Both the RING and PRY/SPRY domains are also 
characteristic feature of some of the TRIM family proteins. Of particular 
interest and relevance is TRIM5α protein reported to play a role in mediating 
innate immunity against retroviruses (Stremalau et al., 2004).  
 HIV-1 can replicate in humans but not in the old world monkeys. The 
virus can enter the macaque cells but was restricted in the early phase before 
reverse transcription. TRIM5α was isolated to be the cytoplasmic factor 
responsible for blocking HIV-1 infection in the macaque cells. The action was 
also found to be specie-specific, whereby only the rhesus macaque TRIM5α, 
but not human, efficiently restricted HIV-1 (Stremlau et al., 2004).  
 The mechanism of action by TRIM5α on the restriction of HIV-1 was 
attributed to two key domains, including the functional RING domain as well 
as the PRY/SPRY domain at the C-terminal of the protein. The PRY/SPRY 
domain is essential for TRIM5α to interact with CA lattice of the retrovirus 
and stimulate the formation of a complementary lattice upon viral entry. It also 
confers a CA-specificity to the TRIM5α protein, in which interspecies 
variation in the binding strength of the latter to the CA of the retrovirus was 
found to correlate with the ability of TRIM5α to restrict that retrovirus in the 
host specie (Stremlau et al., 2006). Upon interacting with the viral CA, the 
RING domain is activated to cooperate with the heterodimeric E2, 
UBC13/UEV1A for the uncoating and proteasomal degradation of the viral 
capsid proteins (Grutter and Luban, 2012), thereby blocking reverse 
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transcription. The RING E3 ubiquitin ligase activity is an essential functional 
domain to the restriction of retrovirus activity. Mutations to this domain that 
alters ubiqutination in the presence of E2 conjugating enzyme did not affect 
TRIM5α association with viral CA, but ultimately disrupted the retrovirus 
restriction activity (Lienlaf et al., 2011).  
Following the observations of the role played by each domain in the 
restriction of HIV-1 infection by TRIM5α, a plausible mechanism of action 
can be extrapolated for RFPL3 in its enhancement of HIV-1 PIC activity, 
based also on the experimental evidence and results we have obtained from 
performing further validation and observation studies on RFPL3 protein.  
4.4.2 Evaluation on the experimental results of RFPL3 
 RFPL3 was the only candidate protein that was able to show a 
significant in vitro modulation of HIV-1 PIC activity that is concentration 
dependent when tested on the microtiter plate-based PIC assay (Section 3.4). 
Hence, RFPL3 was identified as a true enhancer of HIV-1 PIC in vitro and 
further studies were then carried out to elucidate the mechanism of action of 
the protein in modulating PIC activity.  
 
The RING domain is responsible for the enhancement effect of RPFL3 on 
HIV-1 PIC activity 
We first attempted to identify the essential functional domain of 
RFPL3 that is indispensable to the enhancement activity on HIV-1 PIC. Three 
N-terminal deletion mutants were generated by wheat germ cell-free system: 
the first with partial removal of its RING domain, the second containing both 
the PRY/SPRY domain and the third with only the SPRY domain. When all 3 
mutants and the full-length RFPL3 were subjected to the same microtiter 
plate-based PIC assay, the full-length RFPL3 could show a significant 
enhancement of PIC activity that of the same level as the positive control 
protein BAF (Section 3.5.1). Since the RING domain is a characteristic feature 
of E3 ubiquitin ligases to interact with E2 conjuating ligases for proteasomal 
degradation of target proteins, and the removal of this domain resulted in a 
loss of enhancement effect in RFPL3, it seemingly suggests that the E3 ligase 
activity of RFPL3 is the determinant of its enhancement effect on HIV-1 PIC. 
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Interestingly, the mutant with partial truncation of its RING domain 
(RFPL3Δ36) was also able to retain minimal enhancement effect as compared 
to the negative control DHFR protein, although it was less than half that of the 
original enhancement strength exhibited by full-length RFPL3. This possibly 
suggests that the C’-terminal stretch of the RING domain also contain 
essential residues that is important for RFPL3 to exert an enhancement effect 
on HIV-1 PIC, whether or not it is due to a retention of its E3 ligase activity. 
Further experiments using C-terminal domain mutants and amino acid mutants 
will be required to assess if the N-terminal RING domain is sufficient and also 
to clarify the essential residues within the domain that are required for the 
enhancement of PIC activity by RFPL3. It is also important to investigate the 
ubiquitinating abilities of each mutant through a ubiquitinylation assay so as to 
allow a study on the correlation of the ubiquitinating ability of RFPL3 with 
PIC enhancement to provide sufficient evidence that RFPL3 is dependent on 
its E3 ligase function in the RING domain to modulate HIV-1 PIC activity, 
perhaps by removing unwanted components that may otherwise perturb the 
subsequent integration reaction.   
 
RFPL3 is not a DNA-binding protein nor an IN interactor, but is likely to 
act on a protein component specific to HIV-1 PIC 
 The HIV-1 PIC consists of viral genome as well as viral and cellular 
protein components though the exact PIC proteins have not been fully 
elucidated. However, it can be observed that many of the known PIC 
components either interact with the viral DNA genome, such as BAF, HMG 
I(Y) and the LEM proteins, or are interactors of viral IN protein, including 
Ku70 and Ku80 (Table 1.2). Hence, we began our association study by 
investigating the DNA-binding ability of RFPL3 to find out if RFPL3 
modulates HIV-1 PIC activity through tethering to the viral DNA. A simple 
DNA-binding assay was performed with random target substrate DNA, using 
DNA-binding BAF as a positive control protein. From Section 3.5.2, the 
southern blot results revealed that BAF could associate with target substrate 
DNA to form a DNA-protein complex of slower migration rate when resolved 
on gel electrophoresis, but no association or complex formation was observed 
in sample containing RFPL3 and target DNA. This led to the conclusion that 
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RFPL3 is not a DNA-binding protein, and probably associates with the HIV-1 
PIC through a protein component.  
Next, we investigated the possibility of RFPL3 being an IN interactor, 
thus directly exerting an enhancement effect on the activity of the key viral 
enzyme that mediates integration reaction. We chose to adopt the 
AlphaScreenTM technology to study in vitro protein-protein interaction due to 
its hassle-free nature, as compared to repeated washes required of 
conventional enzyme-linked immunsorbent assay (ELISA) (Mai et al., 2002). 
Additionally, the excitation range of the donor-acceptor beads has a 
significantly larger proximity limit of 200 nm, making it a much more 
powerful tool to monitor interactions over wide variety of biomolecular 
targets, as compared to the proximity limit of 7 nm in fluorescence resonance 
energy transfer (FRET) assays (Glickman et al., 2002). From the results, even 
though the luminescence signal detected from RFPL3 and recombinant IN was 
slightly higher than that of the DHFR control, the difference was not 
statistically significant (p=0.13), unlike that of the known IN interactor 
LEDGF (Section 3.5.4). Hence, RFPL3 was observed to have low affinity 
with recombinant IN in vitro and is unlikely to associate with HIV-1 PIC 
through the viral IN protein.  
It is however noted that both the DNA affinity and IN-interaction 
studies were performed using protein amount and conditions as optimised for 
the respective positive control proteins, BAF and LEDGF in both experiments. 
Hence, there is a possibility that insufficient protein amount may be a limiting 
factor to the results obtained. Further experiments using higher concentrations 
of the RFPL3 protein should be carried out to confirm the true in vitro affinity 
for DNA and HIV-1 IN, respectively.  
We also checked the target specificity of RFPL3 in its enhancement of 
PIC activity by using MoMLV PIC instead of HIV-1 PIC for the microtiter 
plate-based integration assay. The MoMLV is the simpler representation of a 
retroviral model that is commonly used in the study of infectious diseases 
involving retroviruses. Hence, if RFPL3 enhances both the MoMLV and HIV-
1 PIC, it is likely to interact with a protein component that is highly conserved 
in both viral species, indicating that it is possibly a viral component rather than 
a cytoplasmic host protein, since both viruses infect fairly different cell-types. 
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However, the enhancement effect by RFPL3 was not reproduced in MoMLV 
PICs (Section 3.5.3), suggesting that the target of RFPL3 is a protein 
component that is unique to HIV-1 PIC. Possibilities include the accessory 
viral proteins that are not present in MoMLV PIC, or probably a host cellular 
factor that is only present in the host target of HIV-1. Since the direct binding 
partner of RFPL3 within the HIV-1 PIC is still unknown, it may thus be 
interesting to carry out interaction studies between RFPL3 and the known IN-
binding cofactor proteins as listed in Table 1.1 for further clarification.   
 
RFPL3 associates with PIC leading to enhanced infectivity in RFPL3-
expressing 293T cells incubated with lentiviral supernatant 
 RFPL3 was found to enhance HIV-1 PIC activity in vitro. This 
suggests a direct association between RFPL3 and the PIC. Cellular 
localization studies performed on 293T cells overexpressing FLAG-tagged 
RFPL3 indeed supported the in vitro observation, since most of the RFPL3 
was found to localize mainly in the cytoplasm of the cell where PICs were 
formed (Section 3.6.1) An intracellular association of the two was indeed 
confirmed through the co-immunoprecipitation of FLAG-tagged RFPL3 with 
PICs isolated from RFPL3-expressing 293T cells infected with HIV-1 vector 
(Section 3.6.2). This suggests that RFPL3 probably interferes with PIC 
activity early in the replication cycle, before it was translocated to the nucleus 
to catalyse the integration reaction. Additionally, RPFL3 is probably not 
directly involved in the integration reaction, but enhances HIV-1 PIC activity 
through an indirect mechanism that hastens the catalysis of integration process 
by the PIC. Lastly, infectivity of HIV-1 carrying luciferase gene to RFPL3-
expressing 293T cells were monitored. As compared to the infected 293T cell-
line overexpressing DHFR control protein, the luciferase activity derived from 
HIV-1 vector infection was significantly higher in cells overexpressing RFPL3 
(p< 0.05; Section 3.6.3). This indicates a better infectivity, whereby viral 
genome integration efficiency is clearly enhanced in cells expressing higher 
amounts of RFPL3, therefore confirming a cellular modulation effect by 
RFPL3 on PIC integration activity in vivo.   
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4.4.3 Proposed model of enhancement of HIV-1 PIC integration activity 
by RFPL3 
Based on the summarized results in the previous section, it could be 
concluded that the RING domain is probably an essential effector domain that 
is responsible for the enhancement of HIV-1 PIC activity by RFPL3. Since the 
RING domain is a characteristic feature that of an E3 ubiquitin ligase, there is 
a possibility that the enhancement is mediated through the degradation of a 
certain target component of the HIV-1 PIC, that may otherwise impede the 
subsequent steps leading to viral genome integration. A direct association of 
RFPL3 has been confirmed to support the previous hypothesis, however the 
target component has yet to be identified. Results have eliminated the 
possibility of RFPL3 interacting with the viral genome, and have pointed 
towards the likelihood of a target protein component that is specific to the 
HIV-1 PIC. Considering the example of how TRIM5α could modulate HIV-1 
replicaiton cycle by associating with the viral CA through its PRY/SPRY 
domain, we hence speculated the possibility of RFPL3 to potentially recognize 
the viral CA similarly through its PRY/SPRY domain. Since the CA protein is 
specie-specific, this may perhaps explain for the lack of effect by RFPL3 on 
MoMLV PIC, as it probably has better binding affinity to only HIV-1 CA 
proteins. Recognition of the viral CA proteins may also explain for the 
association between RFPL3 and the HIV-1 PIC, bringing RFPL3 in closer 
proximity to its targeted protein component for proteasomal degradation, 
mediated by its effector RING domain. The degradation of the unknown target 
protein is probably essential to relieve a potential restriction on integration 
activity, perhaps a factor that may otherwise cause instability to either the 
essential viral IN enzyme or the viral genome both of which constitute the key 
players of the integration reaciton.   
In summary, we propose that RFPL3 is a cytoplasmic enhancer of 
HIV-1 PIC, which associates with the latter, thereby allowing the RING 
domain of RPFL3 to exert its E3 ubiquitin ligase activity on an unknown 
protein target within HIV-1 PIC. The relief of the unknown target is believed 
to allow for an enhancement of PIC activity, possibilly through the 
stabilization of key proteins required to protect the integrity of the viral 
genome or IN protein or even a direct removal of restriction factors on these 
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key components, thereby facilitating a more efficient integration reaction 
thereafter. Since viral infectivity was found to be increased in infected cells 
overexpressing RFPL3 (Section 3.6.3), there may be a posibility of an 
upregulation in the gene expression of the integrated viral DNA, although 
further works have to be done to clarify the exact other steps in which RFPL3 
may regulate within the HIV-1 replication cycle (Figure 4). 
 
 
Figure 4: The proposed mechanism of action by RFPL3 in modulating HIV-1 PIC and 
its effect on early HIV-1 replication cycle. The HIV-1 PIC is formed in the cytoplasm of the 
infected cell right after the completion of the reverse transcription of the viral RNA genome. It 
is found to consist of the viral DNA (blue), the dimeric form of the IN (red) and other viral 
proteins as well as a series of cellular factors that have yet to be fully elucidated. RFPL3 
(pink) is thought to associate with HIV-1 PIC specifically in the cytoplasm. It can be 
hypothesized that upon the association of RFPL3 with the PIC, the RING domain might be 
activated to facilitate the ubiquitination and subsequent degradation of a protein component 
within the PIC. The target protein however remains unknown, but can be stipulated to be 
either a protein that restricts the action of IN, or one that blocks the access of stabilizing 
factors to the viral genome, so as to facilitate a hassle-free environment for enhanced viral 
integration. It also remains unknown whether RFPL3 causes an upregulation of HIV-1 




CHAPTER 5: CONCLUSION AND FUTURE WORK 
5.1 Summary of results 
  In conclusion, the results and findings that arose from this partcular 
study can be summarized as follows:  
1. A novel in vitro platform for the survey of cellular factors modulating 
the HIV-1 PIC has been established, in conjunction with a rapid 
protein production method through the wheat germ cell-free system. 
 
2. Multiple rounds of screening had been performed with 135 purified 
human RING-type E3 ubiquitin ligases from a library of 200 clones. 
 
3. Eight candidate HIV-1 PIC modulators had been identified from the 
preliminary rounds of screening, including RFPL3, TRAF5 and 
TRIM61 as potential enhancers and RNF25, STUB1, TIRM52, 
MYLIP and RSPRY as potential inhibitors.  
 
4. Out of four of the candidates tested, only RFPL3 was able to exhibit a 
concentration-dependent enhancement effect on HIV-1 PIC from the 
microtiter plate-based integration assay using E.coli derived proteins.  
 
5. Through domain mutant analysis, the RING domain of RFPL3 was 
identified to be the essential effector domain required for the protein to 
exert an enhancement effect on HIV-1 PIC. 
 
6. RFPL3 is not a DNA-binding protein, and is likely to interact with the 
HIV-1 PIC through a protein target. 
 
7. Since RFPL3 cannot enhance the activity of MoMLV PIC, the target of 
action is likely to be HIV-1 specific, probably one of the accessory 
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viral proteins that is only present in HIV-1 or a cellular factor specific 
to the host cell target of this retrovirus.  
 
8. RFPL3 has low binding affinity to recombinant HIV-1 IN in vitro, 
indicating that RFPL3 probably does not associate with HIV-1 PIC as 
an IN interactor. 
 
9. Cellular localization studies using 293T cells overexpressing RFPL3 
revealed that the protein mainly localizes in the cytoplasm where HIV-
1 PIC is formed, further supporting an interaction between the two. 
 
10. A true cellular association was eventually established through a 
successful co-immunoprecipitation of RFPL3 with PICs isolated from 
lentiviral-infected 293T cells overexpressing RFPL3.  
 
11. Overexpression of RFPL3 in 293T cells also led to higher infectivity as 
observed from an increase in the luciferase activity when these cells 
were infected with HIV-Luc viral supernatant. This suggests a true 










5.2 Future work 
1. Further screening studies can be performed with other protein 
libraries including protein kinases, phosphatases and transcription 
factors. The choice of proteins is due to the fact that most of the 
known cellular cofactors of PIC are either kinases, phosphatases, 
ubiquitin ligases or transcription factors (Turlure et al., 2004). 
Furthermore, these are crucial proteins that modulate the function, 
stability and activity of other cellular proteins, thus there is a higher 
chance of these factors being part of the crew to affect the activity 
of HIV-1 PIC.  
 
2. Concentration-dependent validation studies can be performed on 
the remaining four candidate proteins, namely TRAF5, TRIM61, 
MYLIP and RSPRY, identified from the preliminary screening of 
Batch B proteins. In addition, concentration studies for inhibitor 
candidates can be repeated with increased concentration of the 
inhibitor proteins to validate their true effects, since the assay 
seemed to be less sensitive to the negative modulators of PIC 
integration activity.  
 
3. Even though the RING domain was identified as the essential 
effector domain of RFPL3, it remains inconclusive whether RFPL3 
exerts its enhancement on HIV-1 PIC activity through its function 
as an E3 ligase, or through other mechanism, such as protein-
protein interaction mediated by the RING fingers. Also, it is not 
known if the RING domain itself is sufficient for the modulation 
effect on HIV-1 PIC. Hence, further studies using C-terminal 
mutants and point mutants of RFPL3 are required to determine the 
responsible domains and amino acid residues sufficient for HIV-1 
PIC activity enhancement. The ubiquitinylating abilities of RFPL3 
mutants should also be checked, along with the enhancement effect 
of each mutant on HIV-1 PIC activity, to see if the abrogation of 
E2 conjugation will affect its ability to enhance HIV-1 PIC activity 
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simultaneously. Only then can we conclude that RFPL3 plays the 
role as an E3 ubiquitin ligase in degrading target proteins, thereby 
stabilizing and enhancing the function of HIV-1 PIC.   
 
4. Knockdown studies should also be performed to confirm the 
cellular enhancement effect of RFPL3 on HIV-1 replication. The 
amount of viral cDNA and integrated products that arise form 
infected studies with RFPL3-expressing cells and knockdown cells 
can be quantified to validate the actual step within the HIV-1 
replication cycle that is affected by RFPL3 under cellular 
conditions. The endogenous level of RFPL3 should also be 
measured with an appropriate antibody when available to check for 
any upregulation in gene expression upon HIV-1 infection.  
 
5. In addition, we have extrapolated the possibility of RFPL3 to 
recognize viral CA protein through its PRY/SPRY domain, as 
inferred from the case for a well-known example, TRIM5α. Hence, 
further interaction studies are required to confirm this hypothesis.  
 
6. Finally, since we already established an association between 
RFPL3 and HIV-1 PIC, further efforts are necessary in order to 
identify the actual target protein within the PIC that RFPL3 
interacts with to mediate the enhancement of HIV-1 PIC 
integration activity. This includes interaction studies to be 
conducted with IN-binding proteins as listed in Table 1.1. 
Collectively, these findings could contribute greatly to an advancement in 
knowledge on the aspects of retroviral integration, especially upon the 
revelation of additional PIC modulators and its components. Consequently, 
further studies to elucidate the exact mechanism of action of RFPL3 and other 
candidate proteins may provide insights into novel therapeutic strategies for 
HIV-1 infected patients, as a complementary treatment with the current 
HAART so as to alleviate the problem of resistance development, and improve 
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A1 Primer information 
 
CellFree primers Primer sequence  
AODA2306 5’-AGCGTCAGACCCCGTAGAAA-3’ 
AODS 5’-TTTCTACGGGGTCTGACGCT-3’ 
pDONR221_1stA4080  5’-ATCTTTTCTACGGGGTCTGA-3’ 
SPU 5’-GCGTAGCATTTAGGTGACACT-3’ 
AODA2303 5’-GTCAGACCCCGTAGAAAAGA-3’ 
AODS-3 5’-CTACGGGGTCTGACGCTCAG-3’  
pDONR221_2ndA4035 5’-ACGTTAAGGGATTTTGGTCA-3’ 




Forward primer  Reverse primer 
RFPL3  5’-GGCTGCACTCTTCCAAGAAGC-3’ 5’-TTGGCCTCCCCAGGACGGA-3’ 
RNF25 5’-GGCGGCGTCTGCGTCTGCA-3’ 5’-GAACCATCCTTAGATTCCAGGC-3’ 
STUB1 5’-GAAGGGCAAGGAGGAGAAGGA-3’ 5’-ATGTAGTCCTCCACCCAGCCATT-3’ 
TRIM52 5’-GGCTGGTTATGCCACTACTCC-3’ 5’-TGATTATAGGCCTTGCTGTGAAT-3’ 
DHFR 5-GGTTGGTTCGCTAAACTGCAT-3’ 5’-TCATTCTTCTCATATACTTCAAATT-3’ 
Table A1.2: Primer sequences for amplification of ORF for candidate proteins selected from preliminary 
screening 
 
S1 primers for 
RFPL3 mutants 
Primer sequence  
GST-RFPL3 FL 5’-CCACCCACCACCACCAATGgctgcactcttccaag-3’ 
GST-RFPL3 Δ36 5’-CCACCCACCACCACCAATGatcaattcgctgcaga-3’ 
GST-RFPL3 Δ98  5’-CCACCCACCACCACCAATGgtggatatgaccttgg-3’ 
GST-RFPL3 Δ148 5’-CCACCCACCACCACCAATGacctgtggccgccact-3’ 




A2 Protein expression profile 












No. Name of protein 







1 TRIM21 80,170 +  
2 MID2 103,919 +  
3 RFPL3 58,189 ++  
4 TRIM69 65,254 ++  
5 RNF32 55,053 +  
6 TRAF2 81,860 +  
7 MARCH2 53,025 +  
8 RNF41 61,905 ++  
9 LNX2 102,004 +++  
10 RNF24 43,210 +  
11 BIRC3 94,372 +  
12 RNF144A 58,860 +  
13 RNF115 59,703 +++  
14 TRIM13 72,988 +++  
15 GTF2H2 70,452 +++  
16 TRIM9 105,211 +++  
17 BIRC8 64,622 +++  
18 TRIM54 66,301 +  
19 ARIH2 83,819 +  
20 RNF5 45,881 +  
21 RBX1 38,274 +  
22 ANAPC11 46,644 +++  
23 PPIL2 85,458 +++  
24 CCNB1IP1 57,544 ++  
25 BFAR 78,738 +++  
26 UBOX5 112,575 +  
27 TRIM52 60,653 ++  
28 STUB1 60,856 +++  
29 RNF183 47,675 ++  
30 NSMCE1 55,724 +++  
31 RFPL1 59,102 ++  
32 RNF208 52,011 ++  
33 RNF185 46,459 ++  
34 TRIM47 70,410 +++  
35 RNF25 77,219 +++  
36 NOSIP 59,172 ++  
37 TRIM60 81,114 +  
38 RNF212 59,365 +  
39 RNF133 68,294 +  
40 MDM4 75,541 ++  
41 ZNF645 74,799 ++  
42 TRIM49 78,888 ++  
43 TRIM42 108,863 +  
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Table A2.1 Protein expression profile of 72 E3 ubiquitin ligases from Batch A. 









44 CBLL1 80,519 +  
45 RFPL4B 55,922 ++  
46 DTX3 63,988 +  
47 RNF130 56,810 +  
48 RNF121 63,029 +  
49 RNF19B 84,504 +  
50 RNF152 48,357 ++  
51 PHF7 69,767 ++  
52 PARK2 68,407 +  
53 TRIM45 88,445 +  
54 RNF217 57,982 +  
55 ZNRF4 72,889 +++  
56 MARCH8 58,939 +++  
57 RFFL 62,561 +  
58 UNKL 51,163  + 
59 RAD18 82,195  + 
60 RNF113A 64,787  ++ 
61 RNF7 38,683  +++ 
62 RNF167 64,299  + 
63 MUL1 65,800  ++ 
64 TRIM43 78,265  + 
65 RNF148 60,397  +++ 
66 TRIM74 54,389  + 
67 PJA1 97,003  ++ 
68 RNF180 73,286  ++ 
70 TRIM59 73,114  + 
71 RNF43 111,722  + 
72 BIRC2 95,900  + 
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No. Name of protein 







1 TRIM31 74,243 ++  
2 RNF114 51,694 ++  
3 RNF141 51,535 +++  
4 RNF138 54,193 ++  
5 RSPRY1 90,180 ++  
6 SIAH1 60,628 ++  
7 PCGF5 55,714 +  
8 MID1 101,251 ++  
9 WHSC1 95,349 +  
10 TRAF4 79,543 +  
11 RAPSN 65,912 +++  
12 TRIM48 50,498 +++  
13 MYLIP 75,911 ++  
14 PCGF1 55,221 ++  
15 SPRYD5 59,724 +++  
16 PCGF2 63,788 ++  
17 RNF40 139,679 +  
18 VPS18 90,959 ++  
19 BMI1 62,949 ++  
20 MARCH9 51,878 +  
21 TRIM5 66,108 ++  
22 TRAF7 92,542 ++  
23 RNF26 73,738 +  
24 RNF14 79,838 +  
25 TRIML1 79,002 +++  
26 DCST1 101,719 +  
27 RNF2 63,655 +  
28 TRIM39 82,375 ++  
29 TRAF6 85,634 +  
30 PEX12 66,797 ++  
31 TRAF5 90,406 ++  
32 RNF11 43,444 +++  
33 MARCH3 54,504 +++  
34 RCHY1 56,083 +++  
35 RNF182 53,402 +++  
36 RBBP6 39,817 +  
37 ANKIB1 67,553 +  
38 LINCR 54,040 +  
39 TRIM34 81,741 +  
40 ATRX 46,084 +  
41 IBRDC2 59,495 +  
42 PDZRN3 42,562 ++  
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Table A2.2 Protein expression profile of 63 E3 ubiquitin ligases from Batch B. 
 (‘+’: Low expression level; ‘++’: Moderate expression level;‘+++’: High expression level) 
 
43 RNF12 92,308 +  
44 TRIM10 81,630 +  
45 BRAP 78,025 +  
46 RNF34 67,641  ++ 
47 DTX2 93,319  ++ 
48 TRIM46 80,752  +++ 
49 BARD1 112,601  ++ 
50 TRIM36 109,041  ++ 
51 MIB1 136,136  + 
52 TRIM61 50,047  +++ 
53 DTX3L 109,555  + 
54 CBLB 135,422  + 
55 ZSWIM2 98,721  ++ 
56 VPS41 124,566  + 
57 RAG1 132,198  + 
58 RNF4 47,319  +++ 
59 MDM2 80,558  ++ 
60 MARCH1 57,757  ++ 
61 LNX1 94,803  ++ 
62 RNF125 44,859  + 
63 RING1 68,429  + 
